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ABSTRACT: 
INTRODUCTION: Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion 
channels expressed in both central nervous system (CNS) and peripheral nervous system 
(PNS) and are involved in fast ACh-mediated synaptic transmission. Neuronal nAChRs are 
pentamers composed of a combination of alpha subunits (α2-10) and beta subunits (β2-4) 
exhibiting diverse structural and functional heterogeneity. nAChRs are shown to contribute to 
the physiological roles of nAChRs in neurotransmitter release and synaptic plasticity. Further, 
they are also implicated in various pathophysiological conditions including Alzheimer’s 
disease, schizophrenia, tobacco addiction and lung cancer.  
α-Conotoxins, a new class of peptides that act as nAChR antagonists have been identified 
from the venom of predatory marine cone snails. α-Conotoxins are a class of short di-sulphide 
rich peptides which specifically target various nAChRs subtypes and are excellent molecular 
probes for identifying the physiological role of nAChR subtypes in both normal and disease 
states. They are defined by their characteristic cysteine framework, CCXmCXnC (Xm and Xn 
represent the number of non-cysteine residues), classifying them into various subclasses.  
 
CHAPTER 3: The α3β4 subtype is shown to be involved in lung cancer, nicotine addiction 
and drug-abusive behaviour. Despite this, the knowledge of the pathophysiological role of 
α3β4 subtypes is limited by the lack of adequate subtype specific probes. To-date only five α-
conotoxins inhibiting α3β4 nAChR subtype are known. Of these, α-conotoxin AuIB 
belonging to a unique 4/6 subclass is the only peptide shown to selectively inhibit α3β4 
nAChR subtype with an IC50 of 2.5µM.  
We report the discovery of new α4/7-conotoxin RegIIA which was isolated from Conus 
regius. RegIIA has a classical ω-shaped globular structure with balanced distribution of 
shape, charges and polarity. RegIIA specifically inhibits ACh-evoked currents of α3β2, α3β4, 
and α7 nAChRs isoforms. The implication of α3β4 nAChRs in various diseases such as lung 
 
2 
cancer and nicotine addiction along with RegIIA being the most-potent α3β4 nAChR 
antagonist to date led us to investigate and improve RegIIA’s selectivity profile at the α3β4 
nAChR subtype. Using alanine scanning mutagenesis and modelling studies, we identified 
critical residues of α-conotoxin RegIIA that interact with the ACh-binding site of α3β2, α3β4 
and α7 nAChRs. 
 
CHAPTER 4: α3β2 and α7 nAChR subtypes play vital roles in various functions, such as 
neuronal plasticity, angiogenesis and gene regulation. α-Conotoxins targeting these receptors 
form excellent probes to understand their physiological roles in normal and diseases 
conditions. Here I describe the pharmacological properties of the novel α-conotoxin LsIA, the 
first peptide isolated from Conus limpusi, a species of worm-hunting cone snail commonly 
found on the south east coast of Queensland, Australia. LsIA is an α4/7-conotoxin with the 
characteristic I–III and II–IV disulfide connectivity. LsIA exhibited selective and potent α7 
and α3β2 nAChR subtype antagonism. In this report, I also examined the structure–function 
relationship of the presence of a unique N-terminal serine at position 2 and C-terminal 
carboxylation. Furthermore, I also investigated the pharmacological implications, involving 
incorporation of the α5 subunit towards the inhibition of LsIA at α3β2 nAChR subtypes. 
 
CHAPTER 5: Novel α-conotoxins of the D-superfamily have only recently been discovered 
and functionally characterized. These were found to be non-competitive nAChR antagonist 
and are naturally dimeric, which makes their blocking mechanism more intriguing. From the 
venom of Conus generalis, we identified a novel αD-conotoxin GeXXA. This toxin is a 
disulfide-linked homodimer of a 10-Cys-containing peptide with each peptide chain made of 
50 amino acid residues. Each polypeptide chain is composed of an N-terminal domain (NTD, 
residues 1-20) involved in dimerization and a C-terminal domain (CTD, residues 21-50). αD-
GeXXA is a non-selective inhibitor of nAChR subtypes exhibiting most potency at the α7 
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subtype with an IC50 of 210 nM. However, for rat and human α9α10 nAChRs, the inhibition 
by αD-GeXXA is irreversible, indicating the tight binding of αD-GeXXA to α9α10 nAChR. 
To get further insight about its inhibition mechanism, the CTD of each chain was isolated and 
tested against various nAChR subtypes. Contrary to native peptide, GeXXA-CTD showed 
selective and reversible inhibition of α9α10 nAChR subtype. This specificity was further 
investigated using hybrid receptors of rat and human α9 and α10 subunits. GeXXA-CTD was 
10-fold less potent on human α9α10 than on rat α9α10 nAChR while similar potency was 
observed with hα9rα10 hybrid receptor indicating significant role of α10 subunit in inhibition. 
These results provide more insight into the novel blocking mechanism of α-D conotoxins. 
 
CHAPTER 6: Conotoxins have emerged as useful leads for the development of novel 
therapeutic analgesics. However, the disulfide connectivity of α-conotoxins can change under 
oxidative and reduced conditions leading to changes in structural conformation. Exploitation 
of these and other peptides in research and clinical settings has been hampered by the lability 
of the disulfide bridges that are essential for toxin structure and activity. One solution to this 
problem is replacement of cysteine bridges with nonreducible dicarba linkages. We explore 
this approach by determining the functional characteristics of dicarba analogues of a novel 
analgesic α-conotoxin Vc1.1 and RgIA which is known to inhibit high voltage-activated 
(HVA) calcium channel currents via GABAB receptors and α9α10 nAChR subtypes. When 
tested, dicarba Vc1.1 and dicarba RgIA analogues showed differential activity wherein the 
[2,8]-dicarba analogues of both Vc1.1 and RgIA were active at HVA calcium channel current 
via GABAB receptors whereas the [3,16]-dicarba analogues retained its activity at α9α10 
nAChR subtypes. These results provide new leads towards the elucidation of the biological 
target responsible for the peptide’s potent analgesic activity. 
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SUMMARY: In the past-decade, nAChRs have been identified as potential drug targets for 
various diseases. However, knowledge about the role of various nAChR subtypes in both 
physiological and pathophysiological conditions is scarce. My research describes the 
discovery, characterization and development of a novel α3β4 antagonist as potential tool 
towards understanding its role in lung cancer. Further, dicarba modification of peptides and 
characterization of new class of α- and αD-conotoxins provide future insights towards drug 
development. 
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CHAPTER 1 
INTRODUCTION 
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1.1 Nicotinic acetylcholine receptors 
1.1.1 The discovery 
After the initial discovery of nicotinic acetylcholine receptors (nAChR) in 1914 by Henry H 
Dale [1]  and Otto Loewi [2], substantial progress has been made to improving our 
understanding of the nicotinic mechanisms brought us a step closer to ever growing 
knowledge hill. Numerous reviews documenting this progress have been published and 
focused on nAChR structure, function, physiology, pharmacological tools and potential 
therapeutic use [3-8]. Ironically, these advances only raised more questions about the 
complexity of the nervous system and neurotransmission, and the contribution of these 
receptors in various diseases, such as Parkinson’s disease, Alzheimer’s disease, 
schizophrenia, epilepsy, dementia and cancer [9, 10]. Today, the major breakthroughs in 
understanding nAChRs seem but a fascinating history tale that starts with the initial discovery 
of the chemical nature of neurotransmission by Claude Bernard, a French physiologist, in 
1857. The complexity of the cholinergic transmission or role of acetylcholine (ACh) was as 
yet unanticipated.  
 
In the mid-1980s, advancements in molecular biology enabled the identification and cloning 
of the genes that encoded the first nAChR from Torpedo marmorata [11]. Since then, more 
nAChR family members have been identified, with 16 genes encoding structurally 
homologous yet distinct nAChR subunits now known [12]. The muscle nAChR was primarily 
isolated, purified and sequenced by Jean-Pierre Changeux from the Torpedo electric organ 
[13]. Consequently, the neuromuscular junction (endplate) for the analysis of nAChR-
mediated neurotransmission became widely used. This enabled physiologists to conduct 
various experiments to improve our understanding of the biochemical nature and physiology 
of neurotransmission.  
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nAChRs are ionotropic channels belonging to the cys-loop superfamily of the ligand-gated 
ion channels [3]. Other ion channels belonging to this superfamily include GABAA, glycine 
(GlyR), 5-HT3 serotonin and zinc-activated receptors, which have similar structural features 
to nAChRs [12]. These features include an extracellular NH2-terminal domain (ECD), four 
transmembrane domains (M1-M4), and a intracellular COOH-terminal sequence (ICD) 
[Figure 1.1] [14]. Structural homology of human nAChRs was found to be evolutionarily 
linked to the ionotropic channels, dating back as far as nematodes and molluscs and to simple 
life forms, such as prokaryotes. [15, 16]. Along with these features, various nAChR subunits 
have high sequence homology with each other. 
 
Figure 1.1: Structural features of Torpedo nAChR (PDB 2BG9 [14]). Schematic 
representation of (A) the pentameric structure of a Torpedo nAChR (B) a nAChR subunit 
showing various structural features (C) Cartoon representation of the three dimensional of the 
α-subunit of Torpedo nAChR generated using PyMol Molecular Graphics System (DeLano 
Scientific LLC.). 
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1.1.2 Subunit diversity 
The nAChR is one of the most well-studied ligand-gated ion channel family members. This is 
due to various multidisciplinary studies, including genetic, protein, microscopic and structural 
studies, that stemmed from earlier studies on the Torpedo electric organ nAChR structure. 
Original studies made two major significant findings: 1) nAChRs from Torpedo have 
remarkable density, enabling the pseudo-crystalline studies of the receptor at 4Ǻ resolution 
[14]; and 2) studies of the crystal structure of a water soluble protein, ACh binding-protein 
(AChBP) [17].  
 
The 16 subunits that have been discovered are broadly classified as muscle or neuronal 
subtypes, based on their tissue expression. Muscle subtypes include α1, β1, δ, γ and ε 
subunits, and neuronal subtypes include α2–α10 and β2–β4 subunits. However, although this 
nomenclature is widely used and provides a simple way to class receptor subtypes, it is being 
discouraged by the International Union of Pharmacology [12]. This is because various studies 
have indicated that more than one neuronal subtype receptor is expressed in various non-
neuronal tissues [18-20].  
 
1.1.3 Receptor structure 
nAChRs are pentameric structures made from various transmembrane subunit combinations. 
The above-mentioned subunits assemble in numerous combinations to form two distinct 
receptors classes, namely homomeric receptors (composed of only α subunits, such as α7) and 
heteromeric receptors (composed of α and β subunits, such as α4β2) [Figure 1.2]. Up until 
recently, only α7, α9 and α10 subunits were believed to form only homomeric receptors [21]. 
However, recent studies have provided evidence of the formation of α7-containing 
heteromeric receptors [22, 23]. The pentameric structure of these receptors was initially 
identified during earlier studies into the muscle nAChRs isolated from the Torpedo electric 
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organ. Only two known muscle nAChR combinations have been characterised, α1β1δγ and 
α1β1δε. These were identified as fetal and adult muscle subtypes, respectively, based on their 
expression levels during the developmental stages [24, 25].  
 
Figure 1.2: nAChR subunits forming (A) homomeric and (B) heteromeric receptors. The 
ACh binding site in each receptor is indicated in red triangles [26]. 
 
1.1.3.1 Extracellular domain/Ligand-binding domain 
As mentioned earlier, nAChRs are ligand-gated ion channels and activated or opened in the 
presence of an endogenous agonist or ligand ACh. The ligand- or agonist-binding site exists 
on the extracellular domain, within the interface of two α subunits (in homomeric receptors) 
or between an α and β subunit (in heteromeric receptors) in the receptor. A nomenclature of 
‘agonist-binding subunit’ for α subunits and ‘structural subunits’ for non-α subunits (β1–β4, 
δ, γ and ε subunits), was used to indicate the presence of the cysteine loop in α subunits. The 
cysteine loop is needed to aid the formation of the functional ligand-binding domain [12]. 
However, this nomenclature was discontinued after it was discovered how vital the non-α 
subunits are in the binding pocket. Today, the α-subunit interface is called the ‘principal’ or 
‘+’ face and the β-subunit interface is called the ‘complementary’ or ‘-’ face [Figure 1.3] [27, 
28].  
 
Our knowledge of the N-terminal domain has developed through various binding and 
functional assays in combination with chemical modification and mutagenesis experiments 
[29-31]. Initial studies of photo affinity labelling (photolysis of covalently bound chemical 
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tags to the active sites of protein molecules) on muscle nAChRs using the Torpedo receptor 
identified key amino acid residues, such as α-Tyr 93, which constitute the agonist-binding site 
[32]. These studies provided an early indication of the hydrophobic nature of the agonist-
binding pocket. In muscle nAChRs, this site was located between the interface of α1-δ and 
α1-γ subunits in fetal form, and α1-δ and α1-ε subunits in adult form [33].  
 
More recently, major improvements in understanding the three-dimensional structure of these 
receptors came through X-ray crystallographic and high-resolution electron microscopy 
studies of the ACh binding protein (AChBP) and Torpedo receptor [17, 34]. AChBP, isolated 
from glial cells of molluscs (Lymnaea), is a small, water-soluble protein. Its features are 
structurally similar to those of the N-terminal extracellular domain of nAChRs, but it lacks 
any of the other characteristics of the cys-loop receptor superfamily. The binding interaction 
of ACh to AChBP is similar to nAChR receptor activation. As such, it has received significant 
attention as it may help improve our understanding of the ligand-binding domain of these 
proteins [35].  
 
AChBP crystal structures revealed that the α subunit plays a major role in the agonist-binding 
site. The Cys-Cys pair present only within the α subunits that form the ‘principal’ face of the 
binding site is essential for ligand binding [Figure 1.3]. Mutation of these residues, Cys191–
Cys192 (Torpedo α subunit numbering), significantly affected receptor function and assembly 
[36]. Furthermore, structural and simulation models revealed conformational changes in the 
Cys-Cys pair of up to ~ 11Ǻ, interlocking the agonist/ligand deep within the binding pocket 
[37].  
 
Along with the mobility of the Cys-Cys pair, a series of conserved aromatic amino acid 
residues in the ‘principal’ face contribute to the agonist-binding site. These residues are 
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labelled and grouped into various loops (indicated in parenthesis): Tyr93 (loop A), Trp149 
and Tyr 151 (loop B), Tyr190 and Tyr198 (loop C). As the numbering indicates, the Cys-Cys 
pair belongs to the C-loop of the ‘positive’ interface [Figure 1.3] [38-40]. It is worth noting at 
this stage that among all of the identified α subunits, α5 and α10 subunits do not form the 
‘principal’ face of the agonist-binding site within the receptor complex. Therefore, despite the 
presence of the Cys-Cys pair, these subunits do not form homomeric or heteromeric 
functional receptors. This may be due to the lack of conservation within the key residues. For 
example, substitution of Asp for Tyr at position 198 of the α5 subunit makes it inactive to the 
nicotinic agonist [41, 42].  
 
Figure 1.3: Cartoon representation of the ligand binding domain between α and δ 
subunit of Torpedo nAChR (PDB 2BG9 [14]).  Amino acids contributing by the α-subunit 
to the ‘principal’ or ‘+’ interface of the ACh-binding pocket (Y93, W149, Y151, Y190 and 
Y198) and those contributed by the β-subunit interface to the ‘complementary’ or ‘-’ interface 
(W54 and L108) are represented in stick, overlayed with sphere representation. The Cys191–
Cys192 of α-subunit is coloured yellow. Image generated using PyMol Molecular Graphics 
System (DeLano Scientific LLC.). 
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1.1.3.2 The transmembrane domain and intracellular domain 
Agonist-bound AChBP crystals significantly contributed to our understanding of the various 
conformational changes within the N-terminal extracellular domain and are a very valuable 
scientific tool [43, 44]. However, the lack of other components, such as a transmembrane 
domain and channel gating, hindered the extrapolation of the information to complete 
nAChRs.  
 
The transmembrane domain of each nAChR subunit is made of four segments, M1–M4 
[Figure 1.1]. These segments are important for channel gating and anchoring the receptor in 
the lipid bilayer. The four transmembrane segments are arranged inside the pentameric 
structure of the receptor with the M2 of all of the five subunits lining the channel pore and the 
M4 of all of the five subunits forming the outer surface of the receptor [Figure 1.4]. This 
arrangement, originally hypothesised after the initial bilayer membrane experiments with 
isolated M2 segments of the Torpedo nAChR, was authenticated only after the electron 
microscopic study of Torpedo nAChR by the Unwin group [14]. While the M2 segment is 
primarily involved with channel gating, M1 and M4 segments modulate receptor assembly, 
function and localisation. Early studies using chimeric M1 and M2 constructs reveal that M1–
M2 coupling is involved in the pentameric assembly of α7 nAChR [45]. This was evaluated 
through simultaneous studies on muscle nAChR, and indicated that the M1 contributes to the 
heterodimer structure of the receptor [46].    
 
The orientation of the M4 to the outer surface of the receptors [Figure 1.4] suggests it has a 
role in receptor localisation through its interactions with lipids and cholesterol in the 
membrane bilayer [47, 48]. Furthermore, scanning mutagenesis studies within this Torpedo 
nAChR segment altered its function and assembly [49, 50]. 
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Figure 1.4: Surface overlayed-cartoon representation of transmembrane domains of 
Torpedo nAChR (PDB 2BG9) [14].  The M2 segment (red) of all five subunits forms the ion 
pore of the channel. The M1, M2 and M4 segments are represented in cyan, blue and green 
colour respectively. α-V255 and α-L251 residues involved in channel gating are represented 
in yellow spheres. Image generated using PyMol Molecular Graphics System (DeLano 
Scientific LLC.). 
 
Although the ligand-binding domain and transmembrane domain are vital for nAChR function 
and assembly, the intracellular domain also significantly contributes to it. However, the 
cytoplasmic loops of M1–M2 and M3–M4 have the distinct role of signal transduction to 
these receptors via phosphorylation. While further validation of this function is required, 
recent studies suggested that potential intracellular proteins, such as Rapsyn, interact with the 
α9 nAChR and modulate its surface distribution [51, 52]. Mutations within the large M3–M4 
intracellular loop of the α7 nAChR significantly reduced receptor function and assembly, and 
mutations in the α3 subunit disrupted the distribution of α3-containing receptors in the 
interneuronal synapse [53, 54]. 
1.1.4 Subunit stoichiometry of nAChRs: structural and functional implications 
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Sixteen nAChR subunits that assemble into homomeric or heteromeric pentamers have been 
identified. Heteromeric receptors exhibit a huge diversity in structure, function and receptor 
localisation, which can be attributed to the various possible subunit stoichiometric 
combinations. To date, about 30 known subunit combinations arranged in various 
stoichiometries have been identified. Thus, homomeric structure of a receptor provides a key 
advantage in structural and functional understanding of the receptor. [55].  
 
Stoichiometry of a heteromeric receptor is defined by the identity of the 5th subunit. For 
example, for the α3β2 receptor, the pentameric structure can assemble the 5th subunit with α3 
or β2, producing a simple stoichiometry of this receptor of either (α4)3(β2)2 or (α4)2(β2)3 
[Figure 1.5]. Complex stoichiometries evolve when other subunits such as α5, α6 and β3 are 
introduced as the 5th subunit, to form (α4)2(β2)2α5, (α4)2(β2)2α6 and α4α6(β2)2β3 receptor 
combinations [Figure 1.5]. In the case of muscle nAChRs, only one subunit stoichiometry 
exist: (α1)2β1δε/γ [14]. While recent studies have highlighted some of the roles played by 
different stoichiometric combinations [5], much is to be learned about their contribution to 
receptor function, pharmacology and physiology. 
 
 
Figure 1.5: Various stoichiometric combinations of a heteromeric receptor [26]. 
 
While the pure mathematical combinations of different subunits represent a complex issue, 
native nAChRs assemble predominantly with specific subunit stoichiometry. For example, 
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single-channel recording and direct biochemical studies of α4β2 nAChR, a major subtype 
expressed throughout central nervous system (CNS), showed assembly primarily in the 
(α4)2(β2)3 stoichiometry [56, 57]. However, this composition can be changed in model 
expression systems, such as Xenopus oocytes, via RNA injection of different subunit ratios. 
Recent studies on recombinant receptors using this technique showed differential agonist 
sensitivity based on the subunit ratio of α4 and β2 subunits used (1:10 or 10:1), along with 
changes in calcium permeability [58, 59]. Similar differences in affinity for both agonist 
(ACh) and antagonist (α-conotoxin AuIB) were observed with α3β4 nAChR stoichiometry 
[60]. Furthermore, recent electrophysiological studies with α5, α6 and β3 subunits revealed 
complex subunit stoichiometries with a unique functional role in the receptors such as 
receptor desensitization and gating (these concepts will be discussed in the next section). The 
β3 subunit was reported to extensively co-localise with the α6 subunit, while forming 
complex stoichiometric combinations [61].  
 
Different α6-containing receptor stoichiometries have been implicated in the pathophysiology 
of neurological disorders, such as Parkinson’s disease [62]. In addition, when the α5 subunit 
is co-assembled with the α3β4 nAChR, calcium permeability increases [63] and nicotine-
evoked dopamine release in synaptosomal preparations containing α4β2 nAChRs is affected 
[64]. Therefore, subunit stoichiometry plays a vital role in the pharmacological and 
physiological role of various nAChR subtypes. 
 
1.1.5 Receptor function, biophysical properties and gating 
Mammalian nAChRs are activated by the natural endogenous agonist ACh binding to the N-
terminal extracellular domain. Upon ligand binding, the receptor undergoes rapid 
conformational changes which transition into channel opening. These receptors are cation 
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selective and modulate mono- and divalent cation influx, depolarising cell membranes and 
creating neuronal excitability.  
 
Various residues within the extracellular, transmembrane and intracellular domains of the 
receptor contribute to the microsecond conformation changes from ligand binding to channel 
gating [3]. M1 and M2 are involved in the gating process, and help determine the ionic 
selectivity of these receptors. Mutagenesis study has shown the presence of charged glutamate 
and valine within M2 and a lack of proline in the intracellular domain of M1–M2 correspond 
with the cation permeability of nAChRs [65].  
 
While there is no direct experimental proof that the receptor changes, the various transitions 
within the protein structure of the receptor are based on computational simulations from 
various mutational and structural studies. The current model [34] describes a rotation or 
torque produced by significant C-loop movement (~ 11Ǻ) when the ligand interacts with the 
agonist-binding site. This torque is transitioned through the receptor, influencing the 
orientation of the M2 that lines the channel pore. These transitions place the receptor in three 
structural states: closed, open and desensitised, which determine the receptor’s functional and 
pharmacological properties and influence various intracellular signalling cascades.  
 
The channel-gating process involves switching from a closed or non-ligand-bound receptor 
state to an open state, with a change in channel pore size from ~ 4Ǻ to ~ 8Ǻ respectively [66]. 
This is accomplished via the transitional torque produced by the extracellular domain and 
transitory shift of hydrophobic residues within the M2 helices. It leads to concurrent influx of 
Na+, K+ and Ca2+ ions, which activates an array of signalling pathways.  
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The pore’s ion-gating function is attributed to two special properties: the near perfect 
arrangement of M2 helices in a radially inward tilt towards the pore axis, and symmetric 
orientation of hydrophobic residues α-Leu 251 and α-Val 255 that constrict to form a narrow 
energetic barrier during the closed state of the receptor [Figure 1.4] [67, 68]. This model was 
evaluated when mutational studies of these residues led to increased channel conductivity 
[69].  
 
The above-mentioned studies provided the first rationale linking the physiological function of 
the nAChR with its biophysical properties. There are two major nAChR biophysical 
properties that modulate its physiological functions. Firstly, the rapid transition of the receptor 
between the closed and open state governs its primary role of fast synaptic transmission. The 
release of ACh and subsequent activation of the nAChR in presynaptic junctions modulates 
the release of other neurotransmitters, such as dopamine and GABA [70, 71]. Secondly, the 
ionic permeability of nAChRs to Ca2+ mediates various downstream signalling cascades [72].  
 
The relative permeability ratio (Ca2+/Na+) of the nAChR is calculated by two methods: 
measuring the shift in reversal potential of nAChR-mediated current under varying calcium 
concentrations [73]; and calcium fluorescence imaging [74]. These techniques indicate the 
highest calcium permeability for homomeric α7 and heteromeric α9/α10 with a ratio of ≥10. 
This ratio was the least for muscle nAChRs at ~ 0.1, while all of the other heteromeric 
receptors exhibited a ratio of ~ 2.0 [75, 76]. While the residues that contribute to the barrier 
within the pore are highly conserved in various nAChR subunits, the relative permeability of 
calcium to sodium ions is affected by the arrangement of residues within the ion conduction 
path of the pore. These residues include α-Glu 262, α-Ser 266 (top end of the pore) and α-Glu 
241 (at the intracellular mouth of the pore), and were identified through mutational and 
electrophysiological studies [77, 78]. This variance in calcium permeability changes the 
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physiological roles played by different nAChR subtypes [79]. The physiological implication 
of nAChR-mediated Ca2+ signalling will be discussed in detail in Section 1.6.  
 
While nAChRs were initially identified in neuromuscular and synaptic junctions, and their 
primary role in fast cholinergic transmission is long established, recent discoveries showing 
non-synaptic nAChR expression significantly expanded the functional scope of these 
receptors [80]. Unlike synaptic junctions, where neurotransmitter levels are highly regulated 
via release and active reuptake producing the instantaneous open and closed transition of 
nAChR, non-neuronal nAChRs are prone to prolonged agonist application. This sustained 
exposure led to the identification of a third state of the receptor: desensitised.  
 
Desensitisation is a process in which the receptor transitions from an open state to an agonist-
bound non-conducting state. The transition rates between these states depend directly on the 
dissociation rates of the agonist. Therefore, this is dependent on the nature of the agonist 
bound and the subunit composition of that receptor. As α and β subunits contribute 
differentially to the pharmacological properties of the receptor, the same is applicable to the 
rate of receptor desensitisation. For example, α7 nAChRs desensitise more quickly than other 
subtypes. Also, incorporating the α5 subunit has been shown to change the biophysical 
properties of all three functional states of a receptor [63, 81].  
 
1.1.6 nAChR-mediated Ca2+ signalling and modulation of neuronal growth 
nAChRs exhibit strong calcium permeability, which is dependent on the receptor composition 
and stoichiometry [59, 76]. Subtypes such as the α7 nAChR can directly raise the cytoplasmic 
calcium levels due to their high permeability; however, indirect calcium influx has also been 
shown to occur due to nAChR-mediated depolarisation. Indirect calcium influx occurs in two 
 
19 
ways: through voltage-dependent calcium channels (VDCC), and being released from calcium 
intracellular stores, such as the endoplasmic reticulum [Figure 1.6] [82, 83].  
 
VDCC-mediated calcium influx occurs at depolarising potentials of > –40 mV, which are 
generated by nAChR activation. Under these conditions, the initial Ca2+ entry via nAChRs is 
augmented and may be functionally complementary, an association that is also observed with 
NMDA receptors [84].  
 
The third process contributing to increased cytoplasmic Ca2+ signal is through calcium 
induced calcium release (CICR) from intracellular stores [83]. While calcium signalling via 
VDCCs is significantly mediated by α7-, α3- and/or β2-containing receptors in neuronal 
ganglia, α7 also increases transient Ca2+ levels independently of VDCCs via CICR. Calcium-
quenching experiments in neurons of substantia nigra pars compacta showed reduced 
cytoplasmic calcium levels when α7 nAChR was activated with choline [85]. Receptor 
antagonists were later used to show that CICR involved ryanodine (RyR) receptors and 
inositol (1,4,5)-triphosphate receptors (IP3Rs) expressed in the endoplasmic reticulum 
[Figure 1.6] [82, 86]. Although the molecular mechanism behind nAChR-activated IP3R-
calcium release is still unclear, secondary signalling molecules, such as Ca2+-dependent 
phospholipase C and Ca2+ -sensor proteins, have been implicated [87, 88]. The various 
mechanisms of cytoplasmic calcium influx reflect a complex and intricate functional coupling 
of nAChRs with RyR and IP3 receptors, which leads to a sustained calcium signal. These 
calcium signals play a vital role in the activation of various downstream signalling processes.  
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Figure 1.6: nAChR-mediated Ca2+ signalling and modulation of neuronal growth. 
Downstream signalling events upon nAChR activation are classed as immediate, interim and 
long-term effects. The calcium ion influx occurs through three ways: nAChR activation, 
VDCC activation and CICR mechanism from calcium internal stores (mediated by RyR and 
IP3 receptors). The Ca2+ influx leads to immediate cell depolarisation and activation of 
various kinases and proteins such as PKC, PKA and Calmodulin. This is followed by 
subsequent activation of downstream signalling molecules, leading to various physiological 
responses such as neuronal plasticity, memory, neuroprotection. 
 
The above-discussed calcium influx is a sequential process occurring in the following order: 
nAChR > VDCCs > ryanodine receptor > IP3 receptors. Therefore, it is only logical for the 
various downstream signalling events upon nAChR activation to be sequential and classed as 
immediate, interim and long-term effects based on their duration and timing.  
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1.1.6.1 Immediate effects 
nAChRs expressed in presynaptic junctions of the peripheral nervous system (PNS) and CNS 
mediate their primary role in fast synaptic transmission. This process not only depolarises 
cells, but also initiates exocytosis either directly or via VDCC activation [Figure 1.6] [89]. In 
addition, nAChRs and VDCCs play physiologically complimentary roles in the regulation of 
neurotransmitter release. In striatal synaptosomes, VDCC mediates nAChR-evoked dopamine 
release [90]. However [3H]noradrenaline release from hippocampal synaptosomes, triggered 
by α3β4 nAChR activation, is VDCC-independent [91].  
 
1.1.6.2 Interim effects 
The two major short-term implications of nAChR activation include regulation of gene 
expression and nAChR desensitisation. CICR-mediated calcium influx activates the IP3 
second messenger system involving various Ca2+-sensor proteins and kinases, such as protein 
kinase C (PKC), is classed as an immediate effect [Figure 1.6]. However, concurrent 
activation of downstream molecules, such as extracellular signal-regulated mitogen-activated 
protein kinase (ERK/MAPK) [Figure 1.6], that has been shown to modulate the gene 
expression of the tyrosine hydroxylase (TH), is defined as a short-term Ca2+-signalling effect. 
TH is a known modulator of neurotransmitter release in catecholamine-containing neurons. 
Prolonged nicotine exposure has been shown to promote TH mRNA expression [92]. In 
addition, the role of nAChRs in the regulation of c-Fos and c-Jun gene expression has long 
been apparent [Figure 1.6] [93].  
 
In synaptic and non-synaptic regions, prolonged exposure of agonist leads to nAChR 
desensitisation. Furthermore, high intracellular calcium levels have been shown to affect 
various desensitisation properties, such as recovery of α7-containing nAChRs in chromaffin 
cells and rat hippocampal neurons [94, 95]. These changes to the nAChR’s biophysical 
 
22 
properties are implicated in synaptic efficacy, and corresponding changes in pathological 
conditions suggest a complex reciprocal relationship [81].  
 
1.1.6.3 Long-term effects 
In a complex scenario, nAChR activation and intracellular calcium influx translates into vital 
physiological functions, such as neuronal plasticity, memory mechanisms, neuroprotection 
and regulation of cell death [79]. Recent studies showed activation of other kinases, such as 
Ca2+ -calmodulin-dependent protein kinase (CaMPK) and cAMP response element-binding 
protein (CREB), was mediated via nAChR and CICR calcium influx [Figure 1.6] [96].  
 
ERK/MAPK is an important molecule, central to various signalling cascades. Activation of 
the ERK/MAPK signalling cascade via nAChR activation is critical for regulating gene 
expression. Disrupting these kinase signalling cascades and consequent modulation of α7 
nAChR expression and function has been implicated in Alzheimer’s disease [97]. Today, α7-
evoked activation of phosphatidyl-inositol 3-kinase (PI3K) and ERK/MAPK is a known 
pathway for mediating neuroprotection and stimulating angiogenesis [Figure 1.6]. This anti-
apoptotic property of nAChR signalling is implicated in various cancers and is currently a 
major target for novel therapeutics [98]. The nAChRs role in cancer is detailed in section 
1.7.3. 
 
The many signalling pathways mediated by direct and indirect calcium influx via nAChR-
activation reflect the complexity, yet specificity, of intracellular mechanisms. While recent 
studies have shed light on these dynamic processes, much is yet to be proven and learnt about 
the exact cellular pathways mediated by various specific nAChR subtypes, to improve our 
understanding of their pathological implications.  
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1.1.8 nAChRs and diseases 
Since their discovery, nAChRs have been extensively researched to build knowledge about 
their structure and function. However, it was only in the past few decades that their true 
nature and complexity has been understood. nAChR subunits have various different 
compositions and stoichiometries, which correspond with specific biophysical and functional 
properties, including tissue distribution. This suggests nAChRs may be involved in a huge 
range of identified and as yet unidentified health conditions. nAChRs are known to be 
implicated in numerous pathophysiological conditions, such as epilepsy, schizophrenia, 
Alzheimer’s disease, Parkinson’s disease, pain, auto-immune disease, lung cancer and 
nicotinic dependence, with other conditions being investigated and identified [3, 7, 99]. Each 
of these conditions involves dynamic cellular interactions with a specific receptor subtype. 
However, only three conditions will be discussed within the scope of this thesis: pain, nicotine 
dependence and lung cancer. 
 
1.1.8.1 nAChRs and pain 
Pain is one of the most common health conditions and affects millions of people throughout 
the world. It is a sensory response to nociception (a neuronal process involving noxious 
stimuli), can be classified as either acute (sudden onset) or chronic (prolonged persistent 
pain), and involves various pain pathways.  
 
Nicotinic acetylcholine receptors have long been implicated in pain mediation, and various 
nicotinic compounds that produce analgesic effects have been identified [100]. The initial 
breakthrough came with the discovery of epibatidine which is a potent analgesic and a 
nAChR agonist, although this drug was discontinued due to its severe side effects [101]. This 
knowledge highlighted an alternative pain target to opioid receptors, which were targeted by 
conventional analgesics. Epibatidine is a potent agonist of α4β2 nAChRs, one of the most 
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abundant subtypes in the CNS, and inhibits the nociceptive signals transmitted through the 
dorsal horn of spinal cord [102]. The α4β2 nAChR’s role as a target for analgesics was further 
established with the discovery of the promising therapeutic candidate ABT-594, a potent α4β2 
nAChR inhibitor that lacks the side effects of opioid-targeting drugs [103, 104]. In 
conjunction with α4 and β2 knockout mice studies, this paved the way for nAChRs to be 
novel therapeutic target in pharmaceutical industry [105] and various compounds that target 
α4β2 nAChRs are currently in clinical trials [5]. 
 
While, α4β2 nAChR subtype is a prominent candidate, recent study showed various other 
nAChR subtypes with α7, α3, α9, α10, β2 and β4 subunits, to be involved in pain pathways 
[106]. This study re-established the role of the α4β2 nAChR subtype in the analgesic efficacy 
of various compounds. However, it also suggested that the α3β2 and α3β4 subtypes have a 
significant role in the analgesia by these compounds. While this study excludes the role of the 
α7 nAChR subtype in pain alleviation, other studies contradict this idea [107, 108]. These 
other studies showed that α7 nAChR subtype activation induces anti-nociceptive in acute pain 
model and anti-inflammatory effects in peritoneal macrophages. This was collaborated by 
further studies in which α7 knockout mice exhibited increased hyperalgesia (an exaggerated 
response to pain stimulus) and pain inflammation [109].  
 
A new mechanism of nAChR-mediated pain modulation via receptor desensitisation has also 
been proposed, and involves direct activation of these receptors. Incorporating auxiliary α5 
subunits in α4β2 and α3β4, increases receptor desensitisation [110].  
 
 
 
 
25 
Finally, α9-containing receptor inhibition by a novel class of conotoxins showed significant 
analgesic effects in peripheral neuropathy pain models [111, 112], and as a result, α9 has also 
been proposed as novel target for analgesic drugs. Conotoxins and their analgesic properties 
will be discussed in detail in the Chapters 6. 
 
1.1.8.2 nAChR signalling and lung cancer 
The pathophysiology of lung cancer has studied for almost half a century. Divided into two 
major types: small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), 
it is the second most frequent and leading cause of cancer-related deaths worldwide. NSCLC 
accounts for 80% of all lung cancer cases [113] and smoking, specifically tobacco intake, has 
been a documented risk factor for lung cancer since the 1950s [114, 115]. Nicotine, polycyclic 
aromatic hydrocarbons and nicotine-derived metabolites, such as 4-(methylnitrosamino)-1-(3-
pyridyl)-butanone (NNK) and N-nitrosonornicotine (NNN), are among the carcinogens in 
tobacco smoke that are primary agents that initiate cancer [116]. Tobacco-related 
tumorigenesis is caused either via the genocentric model, in which genomic interaction of 
nicotine and carcinogenic nitrosamines leads to DNA adduct formation and mutation [117], or 
the biochemical model, in which tobacco-derived nicotine and nitrosamines act as potent 
nAChR agonists [118] and mediate the cell signalling pathways of growth, proliferation [119] 
and apoptosis [120]. The biochemical model also leads to various biological effects, including 
nicotine addiction and dependence [121].  
 
1.1.8.2.1 Role of α3 subunit 
Following the Schuller group’s first report in 1989, which implicated nAChRs in the 
regulation of cancer cell growth [119], many studies started exploring the role of nAChRs in 
cancer development and progression. In 1998, Schuller’s group conducted radiolabelled 
binding assay studies using [125I]α-BTX and [3H]EB. These studies conclusively showed that 
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NNK and NNN, tobacco-specific carcinogenic nitrosamines, were potent nAChR agonists 
[118]. At this point, concentrations of these nitrosamines were known to be 5000–10,000 
times greater than nicotine in tobacco smoke, with the NNN concentration two–three times 
that of NNK [117].  
 
The binding assay experiments in this study also revealed the selective binding profile of 
these nitrosamines. NNK was found to be a high-affinity ligand of the α-BTX-sensitive α7 
nAChR subtype, while NNN is selective to the α4/α3 nAChR subtype, classified as an EB-
sensitive neuronal nAChR [Figure 1.7]. Also, the proliferation assay, which used the 
incorporation of [3H]thymidine, identified that NNK’s binding to the α7 nAChR subtype is a 
potent mitogenic stimulus. However, NNN and nicotine showed no effect in the proliferation 
assay. These results, along with previous studies showing apoptotic inhibition of lung cancer 
cells by nicotine, provided strong evidence that nAChRs are involved in tumour progression 
[120].  
 
Consecutively, NNK and nicotine were also shown to have a direct biochemical effect on 
rapid Akt activation in normal human airway epithelial cells (NHBE) [122]. Serine/Threonine 
kinase Akt is a key regulator of cell cycle process. Its activation leads to various signalling 
cascades involved in cell proliferation and apoptosis [123]. This was confirmed by Dennis’ 
group, which demonstrated constitutive activation of Akt/protein kinase B in 90% of NSCLC 
cell lines [124] and increased phosphorylation of downstream Akt substrates, such as MDM2, 
mTOR and NFκB [Figure 1.7] [125]. This is known to promote cellular survival, resistance 
to chemotherapy and radiation, and NFκB-dependent apoptotic inhibition.  
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Figure 1.7: nAChR mediated signalling pathway involved in lung cancer and their cells 
of origin. A summarised model of the various cellular signalling molecules involved in SCLC 
and NSCLC, mediated by the activation of α7 and heteromeric α3-containing receptor such as 
αβ34 nAChRs. Activation of α7 nAChR by NNK or nicotine has shown to enhance cell 
proliferation via β-Arrestin-SRC pathways involving the activation of Raf1 and ERK family 
of kinases. Whereas, α7 and α3-containing receptor mediated activation of Akt, contribute to 
the anti-apoptotic properties of NNK, NNN and Nicotine. 
- kinases; - transcription factors; - IAP proteins  
 
In 2003, Dennis’ group provided the first evidence that nAChR stimulation causes Akt 
overexpression in NSCLCs [122]. It also conclusively provided the first indication that α3 
antagonists are potential therapeutic drugs towards NSCLC. Treatment with NNK and 
nicotine, led to rapid activation of Akt in NHBEs. This action was attenuated in the presence 
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of the α3/α4 antagonist DHβE, but not the α7 nAChR antagonists α-BTX and MLA, which 
showed no effect. Further, Akt phosphorylation increases in NHBEs were observed in the 
presence of an α3-specific agonist, α-ATX [126]. This supports the idea that nicotine causes 
α3-mediated Akt activation. This was later confirmed by Arredondo’s study, in which 
mecamylamine (Mec), a nAChR antagonist effectively abolished NNN’s pathobiologic 
effects in BEP2D cells [127]. 
 
1.1.8.2.2 Physiological to biochemical translation: cellular difference mediated by α7 and 
α3 subunits 
SCLC and NSCLC exhibit different physiological profiles as well as different major 
histological types. NSCLCs show constitutive Akt activation, increased NFκB-dependent 
cellular survival and inhibition of apoptosis, mediated by α3/α4 nAChR subunits and due 
primarily to the agonist effects of tobacco carcinogens NNN and nicotine. Concurrent studies 
show that NNK’s tumorigenic effects are mediated by the α7 nAChR subtype predominantly 
in SCLC, but also in NSCLC [128, 129]. Molecular studies show that α7 nAChR expression 
in SCLC and pulmonary neuroendocrine cells (PNEC) is high [128], which is consistent with 
α7 nAChR expression being upregulated as a result of chronic NNK exposure [130]. These 
results, in conjunction with previous binding studies, show tumorigenesis in SCLC and 
PNECs is mediated via the α7 nAChR subtype, while both α7 and heteromeric α3 nAChR 
subtypes are involved in NSCLC and peripheral adenocarcinoma (PAC) [118, 129].  
 
An in vitro proliferation assay of PNECs or SCLC in the presence of nicotine or NNK 
induced a serotonergic autocrine loop, which was abolished when an α7 nAChR antagonist or 
serotonin uptake inhibitor was added [131, 132]. This autocrine response involved the 
activation of cellular regulators the serine/threonine kinase RAF1, protein kinase C (PKC), 
mitogen-activated kinases ERK1 and ERK2, and transcription factors FOS, JUN and MYC 
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[Figure 1.7] [129, 131, 132]. Along with studies that show pharmacological inhibition of 
these regulators block the proliferation and apoptosis response identified α7 as the key 
regulator of cell proliferation [133, 134]. However in NSCLC, NNK-induced cell 
proliferation activated signal transducers, transcription 1 (STAT1), NFκB, GATA3, β-
arrestin-SRC, and ERK1 and ERK2 [Figure 1.7] [127, 135]. While, NNK’s anti-apoptotic 
activity in SCLC was modulated by activating Bcl-2, in NSCLC, E2F1-mediated upregulation 
of survivin and X-liked inhibitor of apoptosis (XIAP) contributed to nicotine-induced 
apoptotic inhibition [Figure 1.7] [134, 136]. However, these results are yet to identify the role 
of IAP (Inhibitors of Apoptosis) proteins (survivin and XIAP) as characteristic signalling 
proteins underlying the anti-apoptotic effect in NSCLC.  
 
1.1.8.2.3 Targeting the α3β4 nAChR: unlocking novel therapeutics for NSCLC 
Previous studies have identified nicotine and its derivatives as potent nAChR agonists and 
highlighted their regulatory role in cancer cell apoptosis [118, 120]. Recent candidate–gene 
analysis and genome-wide association studies (GWAS) have also identified gene clusters and 
single nucleotide polymorphisms (SNP) encoding α3, α5 and β4 nAChR subunits associated 
with lung cancer [118, 137]. These studies showed the existence of CHRNA5/A3/B4 gene 
cluster overexpression and other specific nAChR subunits in lung cancer tissue [138, 139]. An 
important transcription factor, ASCL1, was shown to play a key regulatory role in the 
initiation and development of SCLC, and the overexpression of the CHRNA5/A3/B4 gene 
cluster [140, 141]. These studies suggest a strong correlation between the overexpression α3, 
α5 and β4 subunits and lung cancer.  
 
NNK and NNN are leading carcinogens involved in the development of lung cancer in 
smokers. Along with nicotine, these nitrosamines have also been shown to be strong nAChR 
agonists and easily displace the endogenous nAChR agonist, ACh [118]. Binding studies have 
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shown that NNK is a selective α7 nAChR agonist, and NNN is a selective agonist of α3/α4-
containing nAChRs [118]. Subsequent studies also showed that expression and activation of 
signalling molecules involved in cell proliferation and the apoptotic inhibition of NSCLC 
increased in the presence of NNN and NNK. This response was abolished when an α7 or α3 
nAChR antagonist was added [124, 136]. More recent GWAS also suggest α3β4 nAChRs are 
key modulators of cell proliferation and apoptotic inhibition of NSCLC [137]. However, a 
lack of adequate molecular α3β4-specific probes has limited the study of the physiological 
role of this receptor subtype in disease progression.  
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1.2. Conotoxins 
The venom of various animals, such as snakes, spiders and molluscs, has long attracted the 
attention of scientists for their ability to kill or paralyse their prey, almost instantly. Most 
venomous animals target invertebrates, with few targeting vertebrates. The venom of animals 
that do target vertebrates has been found to be dangerous – even fatal – to humans. Various 
bioactive peptides, called conotoxins, in the venom bind selectively and potently to different 
ion channel receptors. This makes them biomedically and pharmacologically significant 
[142]. 
 
Figure 1.8: Predatory marine cone snails (A) Conus regius [143] and (B) Conus victoriae. 
 
Predatory marine snails of the genus Conus from the Conoidae superfamily, is one of the 
largest and most diverse genera, with around 500 snail species [Figure 1.8]. Few snails in this 
genus prey on vertebrates like fish. Their venom, which includes thousands of conotoxins, 
also targets different ion channels in humans. α-Conotoxins, a conotoxin subclass found in 
this venom, are short, disulphide-rich peptides that selectively target different nAChR subtype 
isoforms [144].  
 
1.2.1 Venom apparatus and biosynthesis 
The vast diversity in conotoxin structure and sequence corresponds to the complex venom 
apparatus and biosynthesis process in cone snails. The cone snails’ general venom apparatus 
 
32 
includes a long, convoluted tubular gland that synthesises venom, a muscular bulb that moves 
the venom, and the proboscis, which helps deliver the venom and consists of various hallow, 
harpoon-shaped radula teeth [Figure 1.9] [143, 145].  
 
Figure 1.9: Schematic representation of cone snail’s venom apparatus representing the 
main parts [146]. 
 
The conotoxin diversity in venom extends from cone snail gene and proteome level to post-
translational modifications. Interestingly, thousands of peptides in the venom are generated 
from a relatively small number of gene families [147]. The genes encoding conotoxins 
translate into a precursor protein molecule consisting of three distinct segments: N-terminal 
signal sequence, a pro-peptide region and the mature toxin sequence. The N-terminal signal 
sequence and pro-peptide region are highly conserved, however, hypermutation is observed in 
the mature toxin sequence [147, 148].  
 
After the gene is translated, various enzymes are responsible for the production of the mature 
toxin. These include protein disulphide isomerase (PDI), peptidyl-prolyl cis-trans isomerase 
(PPI), cysteine-rich protease Tex31 and immunoglobulin-binding protein (BiP). Recent 
studies have identified various PDI isoforms that contribute to the conotoxins diversity at 
proteomic level [149]. In addition to this variability in the mature toxin sequence, mature 
peptides can undergo post-translational modifications, such as C-terminal amidation and 
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proline hydroxylation, which confers a unique functional activity compared with unmodified 
sequences [150, 151]. 
 
Due to their potential pharmacological significance, it is vital to find a way to effectively and 
accurately synthesise conotoxins in vitro and characterise their structure and function. 
Understanding the diverse post-transcriptional and post-translational regulation of cone snail 
venom biosynthesis will provide important information that will help to improve in vitro 
synthesis of complex conotoxins. 
 
1.2.2 Classification and nomenclature 
The venom repertoire of cone snails is mainly constituted of disulphide-rich conopeptides and 
are categorised into various superfamilies and classified by their structural and functional 
features, such as cysteine pattern and pharmacology. Figure 1.10 illustrates some of these 
superfamilies. This classification is also used to name conotoxins.  
 
The first nomenclature guidelines were introduced in 1985 and updated several years later 
[152]. They outline that conotoxins that have been functionally characterised should be 
labelled with (in the order listed below):  
• a Greek letter indicating their pharmacological target 
• one (uppercase) or two letters (second letter is lowercase) from the Conus species from 
which the peptide was isolated 
• a Roman numeral indicating the cysteine framework pattern  
• an uppercase letter representing the peptide variant discovered in respective cone species.  
 
For example, α-RgIA represents a conotoxin isolated from Conus regius with cysteine 
framework I that targets ACh receptors. 
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Figure 1.10: Classification of conotoxins. The classification of conotoxins into various 
superfamilies is based on their cysteine pattern and pharmacology. Subclass α- and αD-
conotoxins discussed in the following chapter of the thesis are boxed in red. Na+ – voltage 
gated sodium channel; K+ – voltage gated potassium channel; Ca+2 – voltage gated calcium 
channel; nAChR – nicotinic acetyl choline receptors [153]. 
 
There has been a significant increase in the number of conotoxins discovered from complex 
venom repertoire due to recent advances in protein and molecular techniques such as high-
performance liquid chromatography (HPLC) and reverse transcription polymerase chain 
reaction (RT-PCR) [154]. The pharmacology of some of these peptides is unknown, so they 
are labelled differently from those that have been functionally characterised. They are labelled 
with: 
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• one or two letters (both lowercase) from the Conus species from which the peptide was 
isolated 
• an Arabic numeral representing the cysteine framework  
• a lowercase letter representing the peptide variant.  
 
For example, before its pharmacological characterisation, α-RgIA was represented as rg1a.  
 
1.2.3 Conotoxin structural diversity 
Along with high sequence hypervariability, conotoxins show structural diversity. The 
disulphide framework of different conotoxin classes translates these peptides into specific, 
rigid, three-dimensional structures [155]. These structures play an important role in 
determining pharmacological properties of a peptide, including its potency and selectivity 
[156]. In the past decade, nuclear magnetic resonance (NMR) has enabled to determine the 
three-dimensional structures of many conotoxins with characteristic cysteine frameworks 
[157]. For example, α-conotoxins of the A superfamily of conopeptides, fold into a ω-shaped 
structure with a characteristic α-helix secondary structure [Figure 1.11(A)], whereas, χ-
conotoxin MrIA of the T superfamily is dominated by β-helix secondary structures [Figure 
1.11(B)] [157, 158]. Conotoxins with three or more disulphide bonds, such as ω-conotoxin 
MVIIA, have complex cysteine knot structures [Figure 1.11(C)] [159]. α-Conotoxins of the 
D superfamily are composed of five disulphide bonds and exhibit dimerization that yields 
complex three-dimensional structures [160]. These characteristic folds reveal critical residues 
that interact with the ion channel and determine the pharmacological activity of conotoxins.  
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Figure 1.11: Structural diversity among conotoxins. Cartoon representation of the three 
dimensional structures of conotoxins (A) α-Vc1.1 (PDB 2H8S) [161] (B) χ-MrIA (PDB 
2EW4) [162] (C) ω-MVIIA (PDB 1MVI) [163]. α-helics are shown in blue, β-sheets in red 
and disulphide bonds are shown in yellow. Images generated using PyMol Molecular 
Graphics System (DeLano Scientific LLC.). 
 
Though rich in cysteines, these residues are buried within the conotoxin’s three-dimensional 
structure, exposing a hydrophobic patch at the surface [164]. The surface-exposed residues 
contribute to overall net charge of the conotoxin. This charge distribution influences the 
peptide’s selectivity and potency for its pharmacological target. For example, α-conotoxins 
with net positive charge target muscle nAChR subtypes, and those with neutral or negative net 
charge target neuronal nAChR subtypes [165].  
 
1.2.4 Conotoxin structure–activity relationship 
Conotoxin diversity enables them to identify various isoforms of ion channels, making them 
excellent probes to study different receptors. α-Conotoxins are excellent examples of this, 
because they specifically and potently target nAChR subtypes [166]. This has increased our 
understanding of the physiological role each receptor subtype plays in normal and disease 
states. In this thesis, I will limit my discussion to α- and αD-conotoxins. 
 
α-Conotoxins range from 12–25 amino acids in length and belong to the A superfamily of 
conopeptides. They are characterised with the CCXnCXmC cysteine framework, where n and 
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m represent the number of amino acids and indicate the subclass of a peptide. Most native α-
conotoxins exhibit I–III and II–IV disulphide connectivity, yielding a ω-shaped, three-
dimensional globular conformation [155]. Although, α-conotoxins exhibit sequence 
hypervariability, conserved residues are observed among various α-conotoxins. Table 1.1 lists 
some of the α-conotoxins that target neuronal nAChR subtypes. Residues in loop1 (residues 
between Cys II and III) are highly conserved, with most peptides showing a –SXPA– motif.  
 
Table 1.1: Sequence alignment of α-conotoxins targeting neuronal nAChR subtypes. 
α-Conotoxin Sequence nAChR selectivity Reference 
Ls1a   SGCCSNPACRVNNPNIC* α3β2≈α7>α3α5β2 [167] 
GID IRDγCCSNPACRVNNOHVC# α7≈α3β2>α4β2 [164] 
ArIB   DECCSNPACRVNNPHVCRRR# α7≈α6β2^>α3β2 [168] 
RegIIA     GCCSHPACNVNNPHIC* α3β2>α3β4> α7 [169] 
OmIA    GCCSHPACNVNNPHICG* α3β2>α7>α6β2^ [170] 
GIC     GCCSHPACAGNNQHIC* α3β2≈α6β2*>α7 [171] 
AuIB    GCCSYPPCFATNPD-C* α3β4 [172] 
RgIA    GCCSDPRCRYR----CR# α9α10>>α7 [173] 
* amidated C-terminus; # carboxylated C-terminus; ^ receptors containing the subunits; 
conserved cysteine framework is indicated in yellow. 
 
Significant interaction between these loop1 residues and the principal face of the receptor was 
identified using X-ray studies of AChBP, ImI, [A10L,D14K]PnIA [Figure 1.12] and 
[A10L]TxIA co-crystal structures [174, 175]. These studies identified that loop1 has a role in 
the peptide’s secondary structure and affinity, and loop2 residues interact with the 
complementary side of the receptor, contributing to the α-conotoxin’s subtype selectivity 
[Figure 1.12] [156].  
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Figure 1.12: AChBP and [A10L,D14K]PnIA co-crystal structures (PDB 2BR8) [176] 
shown in (A) surface representation and (B) cartoon representation. Mutated residues 
Leu10 and Lys14 of loop2 (green) interact with the (-) interface (orange) while Leu5, Pro6 
and Pro7 residue side chains of loop1 (cyan) have shown to interact with the ‘principal’/(+) 
interface (blue) of the ACh binding pocket. Disulphide bonds of the conotoxin and Cys-Cys 
pair of (+) interface are indicated in yellow. Images generated using PyMol Molecular 
Graphics System (DeLano Scientific LLC.). 
 
1.2.4.1 Use of alanine scanning mutagenesis 
To date, most mutational studies have involved replacing various non-cysteine residues with 
the inert residue alanine. These experiments provided vital information about the various α-
conotoxin residues that interact with receptors, and in combination with modelling simulation 
studies, they have helped to determine α-conotoxin pharmacological selectivity [166]. For 
example, loop2 residues (11–15) in Vc1.1 have been shown to be important for its activity at 
α9α10 nAChR subtypes. Alanine mutation of these residues causes significant loss in activity 
at this subtype [177]. In RgIA, similar experiments showed an approximate 1500-fold loss in 
activity for [R9A]RgIA at the α9α10 subtype. Surprisingly, the opposite effect was seen at the 
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α7 subtype, with an approximate 5-fold increase in activity [178]. This mutation was 
homologous with that of α4/3-conotoxin ImI, which selectively inhibits α7 and α3β2 nAChR 
subtypes [179].  
 
Alanine scanning mutagenesis not only contributed to the molecular basis for various 
conotoxins’ antagonism of their respective nAChR subtypes, but also significantly improved 
our understanding of these peptides’ subtype selectivity. Furthermore, alanine mutation 
improved α-conotoxin potency and selectivity. For example, E11A mutation in α-conotoxin 
MII improved its selectivity and potency towards α6-containing nAChRs [180]. In Vc1.1, 
N9A mutation increased potency at α9α10 nAChR subtypes about 10-fold [177]. 
 
1.2.5 Conotoxin re-engineering 
α-Conotoxin use in research and clinical settings has been hampered because of their peptidic 
nature, which makes them susceptible to natural degradation, such as proteolytic attack, or 
disruptions of their disulphide connectivity. These problems drastically affect their 
bioavailability and half-life. In vitro chemical synthesis of conotoxins allows them to be 
chemically modified to improve their structure and ability to be used in research and clinical 
settings.  
 
1.2.5.1 Dicarba modification 
Various strategies to improve α-conotoxin stability have been implemented, such as 
cyclisation and selenocysteine modification [181, 182]. Recent studies have shown that 
replacing the cysteine bridges (S–S motif) with non-reducible dicarba links (CH2–CH2, 
CH=CH groups) [183] is a novel way to improve stability and resistance to peptide 
degradation and scrambling [184]. In addition, this modification maintains the 
pharmacological activity of α-conotoxins [185, 186].  
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1.2.6 Conotoxins: potential therapeutics 
That conotoxins selectively and potently inhibit various ion channels has put them at the 
forefront of novel drug development. Several conotoxins are, and have been, tested clinically 
to treat a range of health conditions, including neuropathic pain and benign prostatic 
hyperplasia [187]. For example, ω-Conotoxin MVIIA, isolated from Conus magus, inhibits N-
type calcium channels [188] and is an FDA-approved drug for pain relief. Peptides 
undergoing clinical trials include χ-MrIA (a non-competitive neuronal noradrenaline receptor 
inhibitor) to treat benign prostatic hyperplasia symptoms [189], and conantokin-G (a selective 
NMDA receptor inhibitor) to manage epilepsy [190].  
 
Recent studies have also identified nAChR subtypes that are involved in various health 
conditions, such as schizophrenia (α7 and α4β2), Parkinson’s disease (α6-containing 
receptors), Alzheimer’s disease (α7 and α4β2), lung cancer (α3β4) and pain (α4β2). These 
discoveries have provided new therapeutic applications for α-conotoxins that target neuronal 
nAChRs [40, 99, 144, 191]. 
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This chapter describes the protocols followed for the synthesis, and structural and functional 
characterisation of conotoxins.  
 
2.1 Materials 
Rink amide methylbenzhydrylamine (MBHA) resin (Novabiochem), O-benzotriazole-
N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU), N-(9-fluorenyl) 
methoxycarbonyl (Fmoc), dimethylformamide (DMF), N,N′-diisopropylethylamine (DIPEA), 
trifluoroacetic acid (TFA), triisopropylsilane (TIPS), ether, HPLC grade acetonitrile (ACN), 
potassium cyanide (KCN), ninhydrin, tricaine methanesulphonate (MS-222), acetylcholine 
(ACh), hydrogen fluoride (HF). 
 
2.2 Peptide synthesis 
2.2.1 Solid-phase peptide synthesis (SPPS) 
Chemical synthesis using SPPS involves building a peptide chain that is covalently attached 
to a solid resin support. This concept was introduced by Merrifield in 1963 [1]. Stepwise 
assembly of the amino acids on the resin uses one of two types of chemistry, depending on the 
N-terminal protecting group of amino acids - 9-fluorenylmethoxycarbonyl (Fmoc) and tert-
butyloxycarbonyl (t-Boc). Along with one of these orthogonal protecting groups, side chain 
protecting groups are also present on amino acids which prevent any intermediate reactions 
during peptide elongation.  
 
Peptide elongation involves two basic steps: N-terminal deprotection and a coupling reaction. 
These steps are where the major differences between Fmoc and Boc peptide synthesis are 
seen. In Boc chemistry, the deprotection step uses an acid, such as TFA, whereas Fmoc 
chemistry uses a base, such as piperidine. The two also require different reactions to cleave 
the peptide from the solid resin. Boc needs HF, while Fmoc uses TFA [1, 2]. Because Fmoc 
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uses low-hazard reagents, it is safer than Boc, which is why many scientists prefer it. 
However, both methods have specific advantages, and the type of SPPS method used depends 
on the final peptide needed.  
 
2.2.2 Fmoc SPPS 
All peptide analogues discussed in Chapter 3 were synthesised using Fmoc chemistry. The 
various steps involved in this method are detailed below. Fmoc peptide synthesis was carried 
out in collaboration with Dr Richard Clark (The University of Queensland, Brisbane).  
 
Our collaborators provided the peptides described in other chapters. 
 
2.2.2.1 Peptide assembly 
The basic apparatus for SPPS includes a reaction vessel with a sintered glass filter and tap at 
the bottom, which is connected to a vacuum line via a solvent trap [Figure 2.1]. The filter 
supports the resin upon which the peptides are assembled. The tap allows solvents to be 
removed from the vessel. 
 
Figure 2.1: The basic apparatus set up needed for solid-phase peptide synthesis. 
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All peptide analogues were assembled on rink amide MBHA resin (Novabiochem; 
0.7 mmol·g−1) using HBTU-mediated manual SPSS with an in situ neutralisation procedure 
for Fmoc chemistry [3]. The amount of resin needed for each reaction was calculated based 
on the scale of peptide synthesised in mmoles and the resin’s substitution value (provided 
with resin).  
Mass of resin = scale in mmoles/substitution value 
 
All peptide analogues were synthesised at 0.25 mmoles scale, where 460 mg of rink amide 
MBHA resin (substitution value of 0.54) was used, calculated using the above formula. The 
resin was allowed to swell overnight, soaked in DMF, and then transferred into the reaction 
vessel. 
 
Each amino acid assembly cycle consisted of Fmoc deprotection with 20% piperidine 
in DMF, followed by Fmoc amino acid coupling using HBTU and DIPEA in DMF. A two-
fold excess of Fmoc amino acids was used in the coupling reactions. Each coupling reaction 
used 2 mmoles of each amino acid. The amino acids are activated by dissolving them in 2 mL 
of 0.5 M of HBTU/DMF solution followed by the addition of 174 µL of DIPEA. When 
DIPEA was added, the amino acid mixture was immediately added to the resin and left for 
10–15 min to allow for efficient coupling.  
 
A Kaiser Ninhydrin test was carried out to determine the coupling percentage [4]. The Kaiser 
Ninhydrin test detects the amount of free amine present on the resin, indicated by the solution 
turning purple. In this test, 3–5 mg of the resin was removed, washed with 50% 
DCM/methanol and then air dried. To this dried resin, 2 drops of 76% w/w phenol in ethanol, 
4 drops of 0.2 mM KCN in pyridine and 2 drops of 0.28 M ninhydrin in ethanol was added. 
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The sample was incubated at 100 oC for 5 min, and then 2.8 mL of 60% ethanol in water was 
added to it before it was briefly centrifuged to settle the resin at the bottom. The solution’s 
absorbance at 570 nm, was then calculated against the reagent blank using ultraviolet-visible 
spectrophotometry. The coupling % was calculated using the following equation: 
% coupling = 100 x (1-(A570 x 200/SV x mass of resin)) 
where, A570 is the absorbance value obtained at 570 nm and SV is the substitution value of the 
resin.  
 
Values > 99% indicated a successful coupling reaction, and peptide assembly continued with 
the addition of the next amino acid [4]. However, the ninhydrin test cannot be used to 
determine the coupling efficiency of an amino acid after proline. This is due to lack of 
primary amines at the N-termini of proline. Under these conditions, the coupling reaction is 
generally either repeated or an Isatin test can be performed to check for coupling.  
 
In the Isatin test, 5 drops of Isatin were dissolved in 3% n-butanol and 2 drops of 10% acetic 
acid were added to the dry resin, before the solution was incubated for 5 min at 100 oC. 
Yellow or colourless resin indicated efficient coupling, whereas a blue or grey-green colour 
represented poor coupling [5].  
 
2.2.2.2 Peptide cleavage  
When the last amino acid was coupled, the N-terminal Fmoc group was removed using the 
usual deprotection procedure and washed with DMF. Peptide cleavage from the dried resin 
(0.4 g) was achieved by treating it with 100 mL of a chemical cocktail composed of TFA, 
TIPS and water (95:2.5:2.5 TFA:TIPS:water v/v/v). TIPS and water within the cocktail are 
scavengers that prevent the modification of unprotected side-chains. The reaction proceeded 
at room temperature (20–23 °C) for 2.5 h. The TFA was then evaporated (not completely 
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dried) and the peptide was precipitated with 30 mL of ice-cold ether. The peptide was then 
extracted using 50% buffer A/B (Buffer A: H2O/0.05% TFA; Buffer B: 90% 
CH3CN/10%H2O/0.045% TFA) using a separating funnel. Any residual ether was removed 
and the peptide was lyophilised [6].  
 
2.2.2.3 Directed disulphide formation 
All peptides were synthesised in globular conformation (I–III; II–IV disulphide connectivity) 
through Fmoc – Cys(Acm) – OH coupling at positions 2 and 8 of the amino acid sequence (I–
III disulphide bond). The scavengers in the chemical cocktail used for cleaving the peptide do 
not deprotect the Acm group on I–III Cys residues. 
 
Crude peptides were purified by reversed-phase high-performance liquid chromatography 
(RP-HPLC) on a Phenomenex C18 column using a gradient of 0–80% B in 80 min, with the 
eluent monitored at 215/280 nm. These conditions were used in subsequent purification steps 
unless stated otherwise. Electrospray mass spectroscopy (ES-MS) confirmed the molecular 
mass of the fractions collected. Those fractions displaying the correct molecular mass of 
linear peptide were pooled and lyophilised for oxidation.  
 
Linear peptides were oxidised in two steps [Figure 2.2]. First, they were dissolved in 
0.1 m NH4HCO3 (pH 8.2) at a concentration of 0.3 mg/mL, and stirred overnight at room 
temperature. This created the II–IV disulphide bond. The Acm protecting groups were stable 
under these conditions. The [II–IV]-disulphide peptides were purified using RP-HPLC, 
confirmed with ES-MS and then lyophilised.  
 
Second, the second disulphide bond (I–III) was formed using the oxidation by iodine method. 
The peptides were dissolved (1 mg/mL) in buffer A (H2O/0.05% TFA) before iodine in 
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acetonitrile was added until the solution turned orange/yellow. The reaction was incubated for 
5 min at 37 oC. Excess iodine was destroyed by adding sodium ascorbate. The oxidised 
peptides were then purified by RP-HPLC using a gradient of 0–80% buffer B over 160 min. 
Analytical RP-HPLC and ES-MS confirmed the synthesised peptides’ purity and molecular 
mass [7]. 
 
            
Figure 2.2: Directed disulphide formation of α-conotoxins using orthogonal cysteine 
protecting groups. 
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2.2.3 NMR spectroscopy 
Dr Richard Clark (School of Biomedical Sciences, The University of Queensland) carried out 
all NMR spectroscopy experiments.  
 
1H NMR was done to determine the successful folding of all peptide analogues outlined in 
Chapter 3. NMR data for all peptides were recorded on Bruker Avance 500- and 600-MHz 
spectrometers, with samples of > 95% purity dissolved in 90% H2O and 10% D2O 
(Cambridge Isotope laboratories, Massachusetts, USA).  
 
Two-dimensional NMR experiments included total correlation spectroscopy (TOCSY) and 
nuclear overhauser effect spectroscopy (NOESY) recorded at 280 K. Spectra were analysed 
using Topspin 1.3 (Bruker) and Sparky software. Most spectra were recorded at pH 3.5. 
Sequence-specific resonance assignment was carried out for each peptide’s spectra in 
collaboration with Dr Norelle Daly (Institute for Molecular Biosciences, The University of 
Queensland) [8]. 
 
2.3 Electrophysiological recordings in Xenopus oocytes 
Xenopus laevis frogs were anesthetised using MS-222 (1.3 g/L) solution before oocytes were 
surgically extracted. The oocytes were then incubated with collagenase (3 mg/mL) dissolved 
in OR2 buffer (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2 and 5 mM HEPES, pH 7.4) for 1–2 
h (until the vitelline membrane surrounding the oocytes was digested). The collagenase was 
then removed by washing the oocytes with OR2 buffer.  
 
Oocytes at stages V–VI (larger in size) with distinct animal (dark) and vegetal pole (white) 
were selected for mRNA injection [Figure 2.3]. cDNAs encoding the rat α3, α4, α9, α10, β2 
and β4 nAChR subunits and human α7 nAChR subunit, subcloned into the oocyte expression 
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vector pT7TS, were used for the mRNA preparation using the mMESSAGE mMACHINE Kit 
(Ambion Inc, USA). All oocytes were injected with 25 ng of cRNA for α9 and α10, and 5 ng 
of cRNA for all other subunits. They were then kept at 18 °C in ND96 buffer (96 mM NaCl, 2 
mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES, pH 7.4) supplemented with 50 
mg/L gentamicin and 100 µg/units/mL penicillin streptomycin for 2–5 days before recording 
[Figure 2.3].  
 
Membrane currents from Xenopus oocytes were recorded using two-electrode voltage clamp 
(virtual ground circuit) with either a GeneClamp 500B amplifier (Molecular Devices) or an 
automated workstation with eight channels in parallel, including drug delivery and online 
analysis (OpusXpressTM 6000A workstation, Axon Instruments Inc.) [Figure 2.3]. Voltage-
recording and current-injecting electrodes were pulled from borosilicate glass (GC150T-7.5, 
Harvard Apparatus Ltd) and had resistances of 0.3–1.5 MΩ when filled with 3 M KCl [9].  
 
Figure 2.3: Schematic representation of the various steps involved in two-electrode 
voltage-clamp studies using Xenopus laevis oocytes. 
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All recordings were made at room temperature using a bath solution of ND96, as described 
above. During recordings, oocytes were perfused continuously at a rate of 2 mL/min, and 
peptides were incubated for 300 s before the ACh was added. ACh (200 µM for α7 and 50 
µM for all other nAChR subtypes) was applied for 2 s at 2 mL/min, with 180–240 s washout 
periods between applications. Cells were voltage-clamped at a holding potential of −80 mV. 
Data were filtered at 10 Hz and sampled at 500 Hz [10].  
 
Desensitisation experiments were carried out using 50 µM ACh applied for 30 s, followed by 
a 300 s washout. The onset (kon) and recovery (koff) from block by the peptide was measured 
by bath applying the peptide at 2 mL/min for 5 min, followed by washout. On-rate kinetics 
were carried out with ACh + peptide pulse applied at the indicated time intervals. ACh pulses 
during recovery from block contained no peptide. The percentage response or percentage 
inhibition was obtained by averaging the peak amplitude of three control responses directly 
before exposure to the peptide. 
 
2.4 Data analysis 
Concentration–response curves for antagonists were fitted by unweighted nonlinear regression 
to the logistic equation: 
Ex = Emax X
nH/(XnH + IC50
nH) 
where Ex is the response, X is the antagonist concentration, Emax is the maximal response, nH 
is the slope factor and IC50 is the antagonist concentration that gives 50% inhibition of the 
maximal response.  
 
All electrophysiological data were pooled (n = 4–8 for each data point) and represent 
arithmetic means ± standard error of the fit.  
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The rates of onset and recovery from block during peptide washout were obtained from 
exponential fits to the data using GraphPad Prism 5. The ki for the peptide was then 
calculated using the equation: 
ki = koff / kon. 
 
Computation was done using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, 
USA).  
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CHAPTER 3 
 
α-Conotoxin RegIIA targeting α3β4 nAChR:  
unlocking novel therapeutics towards lung cancer 
 
Conus regius 
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3.1 INTRODUCTION 
3.1.1 Nicotinic acetylcholine receptors 
Nicotinic acetylcholine receptors (nAChR) are ligand-gated ion channels expressed in the 
central nervous system (CNS) and peripheral nervous system (PNS) [1, 2]. They are 
pentameric receptors composed of a combination of alpha subunits (α2–10) and beta subunits 
(β2–4). nAChRs exhibit a diverse structural and functional heterogeneity through formation 
of various heteromeric (e.g. α3β2 and α4β2) and homomeric isoforms (formed by only α7 and 
α9 subunits) [3]. Their physiological role is well understood and they are known to modulate 
pre- and post-synaptic transmission in the CNS, and visceral and somatic sensory 
transmission in the PNS [4-6].  
 
nAChRs have been implicated in various pathophysiological conditions, including 
Alzheimer’s disease, schizophrenia, tobacco addiction and lung cancer [2]. Despite 
considerable progress in understanding these pathological conditions, knowledge of the 
distribution and neurophysiological role of individual receptor subtypes is limited by the lack 
of adequate isoform-specific probes [7].  
 
3.1.2 The pathophysiological role of the α3β4 nAChR subtype 
Following the first report by Schuller’s group in 1989, which suggested that nAChRs may 
have a role in regulating cancer cell growth [8], many studies were initiated to investigate the 
role of nAChRs in cancer development and progression [9]. Two reports identified nicotine 
and its derivatives as potent nAChR agonists and their regulatory role in cancer cell apoptosis 
[10, 11]. Genome-wide association studies (GWAS) led to the identification of various single 
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nucleotide polymorphisms (SNP) within a gene cluster encoding α3, α5 and β4 nAChR 
subunits, and these SNPs are associated with lung cancer [9, 12]. In addition, the α3β4 
subtype has been shown to be involved in nicotine addiction and drug-abuse [13]. However, 
knowledge of the distribution and physiological role of the α3β4 subtype is still limited. The 
development of a α3β4 subtype-selective inhibitor, which could help develop drugs to treat 
cancer and nicotine addiction, is very desirable. 
 
3.1.3 α-Conotoxins targeting neuronal nAChRs 
Conotoxins are bioactive peptides isolated from the venom of cone snails belonging to the 
genus Conus [14, 15]. α-Conotoxins, a class of short disulphide-rich peptides from this venom 
[16], specifically target various nAChR subtypes and are excellent molecular probes for 
identifying the physiological role of nAChR subtypes in normal and disease states [17]. To 
date, many α-conotoxins have been characterised, and their structural and functional 
properties are well documented in various reviews and online databases 
(http://www.conoserver.org) [14, 18-22]. While it is evident that α-conotoxins, such as ImII 
and MII, exhibit selective inhibitory activity at α7 [23] and α3β2 [24] nAChR subtypes 
respectively, most known peptides target multiple subtypes [25]. Mutagenesis experiments 
have therefore become an important tool to improve the selectivity and potency of these 
peptides [26]. Furthermore, α-conotoxin AuIB is the only peptide known to selectively target 
the α3β4 nAChR subtype with an IC50 of 2.5 µM [27]. 
 
Here, I describe the discovery, and biochemical, biophysical and functional characterisation, 
of RegIIA. This α4/7-conotoxin was isolated from the venom of Conus regius, a worm-
hunting cone snail species that inhabits the Western Atlantic Ocean. It is one of the most 
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potent α3β4 nAChR antagonists, but does not inhibit the α4β2 subtype. This selectivity profile 
makes RegIIA a prospective probe for studying nicotine addiction processes.  
RegIIA has a classical α-conotoxin globular structure (ω-shaped fold) indicating that it has an 
exquisite balance of shape, charges, and polarity exposed on its surface to enable it to potently 
block the α3β4 nAChR. The pathophysiological association of α3β4 nAChRs in various 
diseases such as lung cancer and nicotine addiction, along with RegIIA being one of the most 
potent known α3β4 nAChR antagonists, led us to investigate and improve RegIIA’s 
selectivity profile at the α3β4 nAChR subtype. Using alanine scanning mutagenesis and 
modelling studies, we identified critical residues of α-conotoxin RegIIA that interact with the 
ACh-binding site of α3β2, α3β4 and α7 nAChRs. 
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3.2 AIMS 
3.2.1 Characterisation of α-conotoxin RegIIA isolated from Conus regius. 
 To determine the pharmacological profile of RegIIA using two-electrode 
voltage-clamp technique in Xenopus oocytes expressing recombinant 
nAChR subtypes. 
3.2.2 Alanine scan mutagenesis.  
 To understand the molecular mechanism and critical residues that 
determine RegIIA’s specific nAChR subtype selectivity. 
 
3.2.3 Significance 
 In conjunction with modelling simulation being done by our collaborators, 
this study could provide a detailed understanding of RegIIA’s molecular 
pharmacology at the α3β4 and α3β2 nAChR subtypes.  
 This study could also provide valuable information to aid the future design 
and development of α3β4-selective drugs to treat lung cancer and nicotine 
addiction. 
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3.3 RESULTS 
3.3.1 Selective α-conotoxin RegIIA inhibition of recombinant nAChR subtypes  
RegIIA selectivity was examined by inhibiting ACh-evoked currents mediated by various 
nAChRs subtypes expressed in Xenopus oocytes. ACh was applied at 5 min intervals and the 
corresponding membrane currents were assessed. The peptide was bath incubated for 5 mins 
before co-application of ACh and the peptide. Synthetic RegIIA (1 µM) completely inhibited 
ACh-evoked current amplitude produced by α3β4, α3β2 and α7 nAChRs [Figure 3.1]. 
However, RegIIA did not inhibit muscle (αβγδ) or α4β2 nAChRs (n = 4–5). RegIIA (1 µM) 
inhibited only 20 ± 5% of ACh-evoked current amplitude of α9α10 nAChR. Concentration–
response curves of RegIIA display the order of selectivity and their corresponding IC50 values 
for α3β2 (11 nM) > α3β4 (47 nM) > α7 (61 nM) [Figure 3.2 and Table 3.1]. 
 
Figure 3.1: Concentration-dependent RegIIA inhibition of ACh-evoked current 
amplitude mediated by (A) α3β2, (B) α3β4 and (C) α7 nAChRs expressed in oocytes.  
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Figure 3.2: Selectivity of α-conotoxin RegIIA inhibition of nAChR subtypes. RegIIA (1 
µM) completely inhibited α3β2, α3β4 and α7 receptors, and inhibited the α9α10 receptor by 
~20%. Concentration–response curves for RegIIA inhibition gave IC50 of 16 nM for α3β2 
(●), 48 nM for α3β4 (▲) and 51 nM for α7 (□). All data represents mean ± SEM; n = 4–7. 
 
Table 3.1: α-Conotoxin RegIIA inhibition of recombinant nAChR subunits expressed in 
Xenopus oocytes. 
 
nAChR subtype IC50 (95% CI) nH 
α3β2 10.7 nM (8.8–12.9) –1.1 ± 0.1 
α3β4 47.3 nM (39.5–56.6) –1.5 ± 0.2 
α7 61.2 nM (47.8–78.4) –1.2 ± 0.2 
α9α10 >1 µM  
α4β2 >1 µM  
αβδγ >1 µM   
RegIIA (1 µM) had no effect on α4β2 or αβγδ, and inhibited α9α10 by only 20%. All data 
represents n = 4–7. 
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3.3.2 Directed peptide synthesis of α-conotoxin RegIIA analogues and NMR 
α-Conotoxins have a conserved Cys-framework. Their three-dimensional structure is 
dominated by a helical structure. In native α-conotoxins, I–III and II–IV disulfide connectivity 
is dominant and folds the peptide into globular conformation [28, 29]. However, α-conotoxin 
disulfide connectivity can change upon oxidation and reduction to form ribbon (I–IV and II–
III disulfide bonds) or beads (I–II and III–IV disulfide bonds). These conformations play 
significant roles in potency and specificity of α-conotoxins at nAChRs [24, 30].  
 
Under normal conditions of solid-phase peptide synthesis, the percentage of a peptide in a 
single conformation varies, which can be undesirable. This problem was solved by using 
amino acids with stable protective groups (Acm) under normal oxidative conditions 
(0.1 M NH4HCO3, pH 8.2). The use of Cys-Acm amino acids at positions 1 and 3 and a two-
step oxidation procedure, yielded the alanine mutants in a globular conformation (I–III and 
II–IV disulfide bonds), shown by HPLC. This was confirmed by 2D NMR (COSY and 
NOESY), which showed the negative 1H shift values between the amino acids 3 and 7 
positions and indicated the presence of α-helix secondary structure [Figure 3.3].  
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Figure 3.3: RegIIA and alanine analogues secondary αH shifts.  
 
3.3.3 Inhibition of nAChR subtypes by α-conotoxin RegIIA analogues: 
To understand the RegIIA structure–activity relationship at nAChRs, RegIIA analogues were 
tested on α3β2, α3β4 and α7 nAChR subtypes at a concentration of 300 nM [Figure 3.4]. 
[H14A]RegIIA showed complete loss in activity at all of the above-mentioned nAChR 
subtypes. At α7 nAChR subtype, no noticeable change was seen for [P13A]RegIIA inhibition, 
whereas inhibition by all other analogues was significantly reduced or completely lost 
[Figure 3.4(B)]. In contrast, no change in inhibition of the α3β4 nAChR subtype by RegIIA 
analogues was observed except for [N9A]RegIIA which completely lost its activity at α3β4. 
Furthermore, [N11A]RegIIA and [N12A]RegIIA selectivity for α3β4 nAChR subtypes 
improved. Their inhibition of the α3β2 nAChR subtype was significantly reduced (by 
approximately 50%), whereas no change was observed at α3β4 nAChR subtype [Figure 
3.4(B)]. This was apparent in the concentration–response curves for [N11A]RegIIA and 
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[N12A]RegIIA, which showed the inhibition curve for the α3β2 (red line) nAChR subtype 
shifted toward the right [Figure 3.5]. The IC50 values for [N11A]RegIIA and [N12A]RegIIA 
at the α3β2 nAChR subtype was 115.9 nM (95% Cl 62.7 – 214.1; nH = –0.9 ± 0.22) and 278 
nM (95% Cl 153.4 – 503.8; nH = –1.1 ± 0.25) respectively, and at the α3β4 nAChR subtype is 
51.6 nM (95% Cl 44.2 – 60.1; nH = –2.0 ± 0.21) and 112 nM (95% Cl 92.1 – 136.2; nH = –1.7 
± 0.32), respectively [Table 3.2].  
 
Figure 3.4. RegIIA and alanine analogue (300 nM) inhibition of various nAChR 
subtypes expressed in Xenopus oocytes. (A) Bar graph of inhibition of nAChR subtypes by 
RegIIA and its analogues. Data represents mean ± SEM, n = 4–6. (B) Two-way ANOVA 
scatter plot illustrating the loss of activity of the RegIIA analogues (300 nM) relative to wild-
type RegIIA at various nAChR subtypes. [H14A]RegIIA completely lost its activity at α3β2, 
α3β4 and α7 nAChRs. [N9A]RegIIA was more selective for the α3β2 subtype than RegIIA 
was. [N11A]RegIIA and [N12A]RegIIA selectivity for the α3β4 nAChR subtype significantly 
improved. All analogues, except [P13A]RegIIA, significantly lost activity at the α7 nAChR 
subtype. *** p < 0.001, * p < 0.05; n = 4–6. 
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Figure 3.5: [N11A]RegIIA and [N12A]RegIIA exhibiting improved selectivity at α3β4 
nAChR subtypes (A) Superimposed traces showing ACh-evoked current inhibition of the 
α3β2 nAChR subtype by 100 nM (i) RegIIA, (ii) [N11A]RegIIA and (iii) [N11A]RegIIA . (B) 
Concentration–response curves for (ii) [N11A]RegIIA and (iii) [N12A]RegIIA inhibition of 
the α3β4 nAChR (black line, open symbols) and α3β2 nAChR subtypes (red line, closed 
symbols). [N11A]RegIIA and [N12A]RegIIA shifted the curve to the right for the α3β2 (red 
line) nAChR subtype, giving an IC50 value of 116 nM and 278 nM, respectively. All data 
represents mean ± SEM; n = 4–6. 
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Table 3.2: RegIIA and analogues inhibition of nAChR subtypes.  
  α3β4   α3β2   α7 
  IC50 (95% Cl) nH   IC50 (95% Cl) nH   IC50 (95% Cl) nH 
RegIIA 47.3 nM (39.5–56.6) –1.5 ± 0.2 
 
10.7 nM (8.8–12.9) –1.1 ± 0.1 
 
61.2 nM (47.8–78.4) –1.2 ± 0.2 
[N11A]RegIIA 51.6 nM (44.2–60.1) –2.0 ± 0.2 
 
115.9 nM (62.7–214.1) –0.9 ± 0.2 
 
ND – 
[N12A]RegIIA 112 nM (92.1–136.2) –1.7 ± 0.3 
 
278 nM (153.4–503.8) –1.1 ± 0.2 
 
ND – 
[N11A,N12A]RegIIA 370 nM (3.09–442.3) –1.7 ± 0.2 
 
9.87 µM (7.9–12.4) –1.5 ± 0.3 
 
21.5 µM (17.1–27.0) –3.1 ± 0.8 
  
 
              
 
IC50 values with 95% Cl. and Hill slope (nH) obtained from concentration–response curves for RegIIA and analogues at α3β2, α3β4 and α7 
nAChR subtypes. All data represent mean of n = 4–6 experiments. ND – not determined. 
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3.3.4 Double mutant [N11A,N12A]RegIIA selectively inhibits α3β4 nAChR subtype 
Double mutant [N11A,N12A]RegIIA was synthesised to better understand the cumulative 
effect of the two residues on nAChR activity. When tested, [N11A,N12A]RegIIA inhibited 
the α3β4 nAChR subtype with an IC50 of 370 nM (95% Cl 3.09 – 442.3; nH = –1.7 ± 0.2) and 
a 7-fold decrease in potency compared with RegIIA [Figure 3.6]. However, at the α3β2 and 
α7 nAChR subtypes, potency decreased by approximately 1,000-fold (IC50 = 9.9 µM) and 
360-fold (IC50 = 21.5 µM), respectively [Table 3.2]. This indicates an approximate 27-fold 
change in selectivity at the α3β2 nAChR subtype, and an approximate 58-fold change at the 
α7 nAChR subtype.  
 
Figure 3.6: [N11A,N12A]RegIIA inhibition of α3β2 and α3β4 nAChR compared with 
that of wild-type RegIIA. Concentration–response curve of [N11A,N12A]RegIIA gave an 
IC50 of 370 nM at α3β4 (▲) and 9.9 µM at α3β2 (■), with an approximate 27-fold change 
in selectivity. All data represents mean ± SEM; n = 4–6.  
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3.4 DISCUSSION 
3.4.1 Conus regius: characterisation of novel α-conotoxin RegIIA 
Since 1994, when the first α-conotoxin ImI was discovered in the worm-hunting Conus 
imperialis and found to target neuronal nAChRs, numerous α-conotoxins have been 
identified and functionally characterised [14, 31]. Most native α-conotoxins have a ω-shaped, 
three-dimensional globular conformation, which results from the two disulfide bonds (I–III 
and II–IV) in the peptide’s characteristic cysteine framework CCXnCXmC (classified as 
cysteine framework I) [29]. The number of amino acids indicated by n and m designate the 
subclass of the peptide. RegIIA belongs to the α4/7 subclass and exhibits the classical ω-
shaped globular structure, with balanced shape, charges and polarity.  
 
Today, various peptides have been identified from the venom of C. regius, a Western Atlantic 
worm-hunting cone snail species that belongs to various superfamilies, of which 8 belong to 
the A-superfamily with the cysteine framework I [32]. The conotoxin composition of C. 
regius venom gained special importance due to the identification of α-conotoxin RgIA, which 
selectively targets the α9α10 nAChR subtype and high voltage-activated (HVA) calcium 
channel currents via GABAB receptors [33]. α-Conotoxin RegIIA, also isolated from C. 
regius, potently inhibits the α3β4 nAChR subtype [34]. HVA calcium channels modulated by 
GABAB receptors are involved in pain pathways and the α3β4 nAChR subtype is implicated 
in lung cancer pathophysiology. This makes the discovery of RgIA and RegIIA very 
significant and puts them at the forefront of potential new therapeutics.  
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3.4.2 Alanine mutagenesis reveals the pharmacological role of the –NNP– motif in 
RegIIA 
RegIIA exhibits high homology to various known peptides [Table 3.8], with two main 
features: an –SHPA– conserved sequence and –NNP– motif. While the –SHPA– conserved 
sequence is observed in the peptides of different subclasses that target various nAChR 
subtypes, the –NNP– motif has been specifically observed in peptides that inhibit α3β2 and 
α7 nAChR subtypes, such as OmIA [35], EpI [36], PnIA [37], TxIA [38] and ArIB [39]. This 
observation corroborates with the most important finding of this study – the alanine mutation 
of the –NNP– motif significantly affected the peptide’s inhibitory activity at α3β2 and α7 
nAChR subtypes. Additionally, the [N11A,N12A]RegIIA analogue is the most potent of the 
α3β4 nAChR subtype-selective peptides.  
  
Alanine mutations at other positions also provided vital information about the structure–
function relationship between α-conotoxins and neuronal nAChRs. Asparagine at the ninth 
position is critical for RegIIA inhibition of the α7 and α3β4 nAChRs, because alanine 
mutation of this residue completely abolished RegIIA inhibition of both nAChR subtypes.  
 
3.4.3 Molecular modelling and molecular dynamics reveal structural topology of α3β2 
and α3β4 nAChRs and residues that interact with RegIIA 
To elucidate the molecular mechanism of RegIIA’s inhibition of the α3β4 nAChR subtype, 
an alanine scan mutagenesis protocol was used. This technique is well established, and in 
conjunction with atomistic molecular dynamics (MD) simulations, it has previously enabled 
spectacular progress in the field of molecular pharmacology [26, 40]. X-ray and NMR studies 
of AChBP–α-conotoxin complexes, and the support of synthetic analogues, promoted the 
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understanding of ligand–receptor interactions [41-44]. The extracellular N-terminal domain 
(ECD) of β2 and β4 nAChR subunits, to which α-conotoxins bind, exhibited a high sequence 
homology (70%). Recent MD simulation studies also reveal a well-preserved structural 
topology of α3β2 and α3β4 nAChRs. However, the ACh-binding pocket interface between 
the α and β subunits was larger in α3β2 than α3β4 nAChR subtypes [45]. This difference 
could signify a distinct shift in [N11A] and [N12A]RegIIA selectivity for α3β2 and α3β4, 
even though both of these residues primarily interact with the α3(+) interface.  
 
To elucidate the structure–function relationship of the alanine scan mutagenesis results, our 
collaborators carried out atomistic MD simulations of [N11A,N12A]RegIIA. The results 
indicated that the double mutant induced a significant loss in contact Y92, S149, Y189, Y196 
residues of the α3 subunit, and W57, and F119 residues of the β2 subunit induced by the 
double mutant. A comprehensive receptor mutagenesis study of various α-conotoxins (MII, 
GID and PnIA) that inhibit the α3β2 nAChR indicated that the β2 subunit pharmacophore, 
comprised of T59, E61, V111, F119 and L121 residues, has a significant role in ligand 
binding [46].  
 
A more recent molecular docking study of α-conotoxin GIC and the ECD of human α3β2 and 
α3β4 nAChR subtypes revealed that all three subunits have residues that interact with the 
conotoxin (α3 subunit: Y92, Y150, Y189 and Y196; β2 subunit: W57, V111, F119 and L121; 
β4 subunit: W57, I111, L119 (Q119 in rat β4) and L121). It is also interesting to note that the 
α3Y196 and β2F119 residues of the α3β2-GIC model were more closely located than the 
α3Y196 and β4L119 residues of the α3β4-GIC model [45]. These results are consistent with 
the MD simulations displaying the loss of pairwise contacts between wt RegIIA and 
[N11A,N12A]RegIIA at α3β2 compared to α3β4 nAChR subtypes. This study provides the 
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first experimental evidence into the molecular pharmacological difference between an α-
conotoxin and these two nAChR subtypes at structural and functional levels.  
 
3.5 SUMMARY AND CONCLUSION 
The CHRNA3, CHRNB4 and CHRNA5 gene clusters encoding the α3, β4 and α5 nAChR 
subunits gained significant importance in recent years. This may be due to the recent genetic 
and physiological studies implicating that the α3β4 nAChR has a direct functional role in the 
pathophysiology of lung cancer and nicotine addiction [9, 12]. While the α3β4 nAChR was 
initially identified in ganglia, recent studies show it is also distributed throughout the CNS 
and other tissues, such as the interpeduncular nucleus and medial habenula [47, 48].  
 
Identifying and successfully synthesising [N11A,N12A]RegIIA, a α3β4 nAChR subtype-
selective antagonist, could help to decipher the physiological role of this receptor. Our study 
also extends the understanding of RegIIA interactions with various nAChR subtypes and 
elucidated the key residues on the toxin and receptor binding sites. This information is 
invaluable in the design and development of α3β4-selective drugs to treat lung cancer and 
nicotine addiction. 
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Table 3.3: Sequence alignment of α-conotoxins targeting various nAChR subtypes.  
α-Conotoxin Sequence nAChR selectivity IC50 for α3β4 nAChR inhibition Reference 
RegIIA    GCCSHPACNVNNPHIC* α3β2>α3β4> α7 50 nM [34] 
OmIA   GCCSHPACNVNNPHICG* α3β2>α7>α6β2 - [49] 
GIC    GCCSHPACAGNNQHIC* α3β2≈α6β2>α7 - [50] 
PeIA   GCCSHPACSVNHPELC* α9α10>α3β2>α6β2*>α3β4>α7 480 nM [51] 
Mr1.1   GCCSHPACSVNNPDIC* α3β2>α3β4>α7 1400 nM [52] 
Ls1a  SGCCSNPACRVNNPNIC* α3β2>α7 - [53] 
AuIB   GCCSYPPCFATNPD-C* α3β4 2500 nM [54] 
BuIA   GCCSTPPCAVLY---C* β2*>β4* 28 nM [55] 
PIA RDPCCSNPVCTVHNPQIC* α6β2*>α6β4≈α3β2>α3β4 520 nM [56] 
ArIB  DECCSNPACRVNNPHVCRRR* α7≈α6β2*>α3β2 - [57] 
     
 
Amino acids homologous to RegIIA are labelled with grey background. Peptides inhibiting the α3β4 nAChR subtype (orange) and their 
corresponding IC50 values are shown. The conserved cysteine framework is highlighted in yellow. 
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CHAPTER 4 
 
Characterisation of LsIA:  
First α-conotoxin isolated from Conus limpusi 
 
Conus limpusi 
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4.1 INTRODUCTION 
α-Conotoxins are a class of bioactive peptides isolated from the venom of cone snails 
belonging to the genus Conus. They inhibit various nAChR subtypes with a high degree of 
specificity and potency. This unique pharmacological profile has led to the development of α-
conotoxins as novel molecular probes for the physiological study of nAChR subtypes and 
drugs to treat various pathological conditions involving cholinergic mechanisms of action [1]. 
The pharmacological profile of an α-conotoxin is determined by the peptide’s structure and 
sequence. α-Conotoxins of the α4/7 and α4/3 subclass, defined by their characteristic cysteine 
framework, inhibit neuronal nAChR subtypes almost exclusively [2].  
  
nAChRs are pentameric transmembrane ion channels. They are constituted by various nAChR 
subunits, which classifies them into homomeric receptors, such as α7 or α9, or heteromeric 
receptors, such as α4β2 or α3β2 [3]. nAChRs primarily mediate fast synaptic transmissions in 
the CNS and PNS. They also modulate cholinergic transmission in non-neuronal cells, 
mediating subtype-specific physiological functions [4].  
 
α3β2 and α7 nAChR subtypes play vital roles in various functions, such as neuronal plasticity, 
angiogenesis and gene regulation [5]. They also are involved in various pathophysiological 
conditions, such as schizophrenia, Alzheimer’s disease and myasthenia gravis [6]. 
 
Here I describe the pharmacological properties of the novel α-conotoxin LsIA, the first 
peptide isolated from Conus limpusi, a species of worm-hunting cone snail commonly found 
on the south east coast of Queensland, Australia. LsIA is an α4/7-conotoxin with the 
characteristic I–III and II–IV disulfide connectivity. LsIA exhibited selective and potent α7 
and α3β2 nAChR subtype antagonism. In this report, I also examined the structure–function 
relationship of the presence of a unique N-terminal serine at position 2 and C-terminal 
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carboxylation. Furthermore, I also investigated the pharmacological implications, involving 
incorporation of the α5 subunit towards the inhibition of LsIA at α3β2 nAChR subtypes.  
 
 
4.2 AIMS  
4.2.1 Characterisation of LsIA. 
 To functionally characterise LsIA – the first α-conotoxin isolated from 
Conus limpusi. 
 To identify the role the N-terminal sequence and C-terminal carboxylation 
play towards the pharmacological profile of LsIA.  
 
4.2.2 Significance 
 To identify and understand the pharmacological profile of novel α-
conotoxins at nAChR. 
 To understand the structure–functional relationship of unique α-conotoxin 
features. 
 To understand the functional implication of α5 subunit in conotoxin 
pharmacology.  
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4.3 RESULTS 
4.3.1 LsIA inhibition of recombinant nAChR subtypes 
I determined LsIA potency and selectivity at neuronal nAChRs by examining its effect on 
ACh-evoked currents mediated by different nAChR subunit combinations expressed in 
Xenopus oocytes. ACh was applied every 5 min and ACh-evoked membrane currents were 
assessed. LsIA (1 µM) completely inhibited ACh-evoked current amplitude mediated by α7, 
α3β2 and α3α5β2 nAChR subtypes. However, LsIA (3 µM) inhibited α3β4 nAChR-mediated 
currents by only 40 ± 5% (n = 6) and had no effect on α9α10 and α4-containing nAChR 
subtypes (n = 4–8) [Figure 4.1].  
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Figure 4.1: α-Conotoxin LsIA selectivity for various nAChR subunit combinations 
expressed in Xenopus oocytes. (A) Superimposed traces of ACh-evoked currents in the 
absence (control) and presence of various LsIA concentrations at α7, α3β2 and α3α5β2 
nAChR subtypes. (B) Concentration–response curves for LsIA inhibition of different nAChR 
subtypes gave IC50 values of 10.3 nM (95% CI, 8.8–12.1 nM; nH  = –1.3 ± 0.1) at α3β2; 31.2 
nM (95% CI, 26.1–37.3 nM; nH  = –1.1 ± 0.1) at α3α5β2; and 10.1 nM (95% CI, 8.7–11.6 nM; 
nH = –2.1 ± 0.4) at α7 subtypes. LsIA (1 µM) completely inhibited ACh-evoked currents 
mediated by α3β2, α3α5β2 and α7 nAChRs. Data represents mean ± SEM, n = 3–6. 
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LsIA reversibly inhibited α3α5β2 about three times less potently (IC50 = 31.2 nM) than it did 
the α3β2 subtype (IC50 = 10.3 nM). α5 subunit expression was confirmed by desensitisation 
experiments described in the Material and methods section. As shown in a previous study [7], 
the time course response of the α3α5β2 nAChR subtype showed notably faster desensitisation 
of ACh-evoked currents compared with those of the α3β2 nAChR subtype [Figure 4.2 Inset]. 
Concentration–response curves for LsIA inhibition of ACh-evoked currents at different 
nAChR subtypes and their corresponding IC50 value exhibit the following selectivity 
sequence: α7 (10.1 nM) ≅ α3β2 (10.3 nM) > α3α5β2 (31.2 nM) [Figure 4.1].  
 
The on- and off-rates (kon and koff) for nAChR inhibition by the peptide were obtained from 
the time course of responses in the presence and upon washout of the peptide [Figure 4.2 and 
4.3 and Table 4.1]. LsIA (10 nM) recovered more slowly from block at the α7 nAChR 
subtype than at the α3β2 and α3α5β2 nAChR subtypes, giving a ki of 1.47 x 10-9 M [Figure 
4.3 and Table 4.1]. This ki value is 6.8-fold lower than IC50. A similar trend was observed at 
the α3α5β2 subtype, which had a ki value 3.3-fold lower than IC50 [Table 4.1].  
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Figure 4.2: Kinetics of LsIA inhibition of peak ACh-evoked current amplitude as a 
function of time. Onset (filled bar) of LsIA (30 nM) block and recovery (open bar) upon 
washout at α3β2 (A) and α3α5β2 (B) nAChR subtypes. Inset: Representative ACh (50 µM)-
evoked currents in oocytes expressing (A) α3β2 and (B) α3α5β2 nAChR subtypes. 
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Figure 4.3: Kinetics of α-conotoxin LsIA block and recovery at the α7 nAChR subtype. 
(A) Representative ACh-evoked currents in the absence and presence of LsIA in oocytes 
expressing α7 nAChR. LsIA (10 nM) was bath applied for 5 min before washout. Responses 
to a 1-s pulse of ACh (200 µM) and toxin for on-rate, and ACh alone for off-rate, kinetics was 
measured at various time intervals. C is the ACh control response before the toxin was 
applied. (B) LsIA inhibition of peak ACh-evoked current amplitude as a function of time. 
Onset (filled bar) of block by LsIA (10 nM) and recovery (open bar) upon washout at the α7 
nAChR subtype.  
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Table 4.1: α-Conotoxin LsIA’s kinetic constants for blocking nAChR subtypesa.  
 kon (min
–1 M–1) koff (min–1) ki (M) IC50 (M) 
α3β2 6.93 (4.99–8.87) x 107 1.052 (0.910–1.194) 15.2 x 10–9 10.3 x 10–9 
α3α5β2 1.26 (0.28–2.24) x 108 1.205 (0.766–1.644)  9.6 x 10–9 31.2 x 10–9 
α7 1.35 (1.17–1.53) x 108 0.199 (0.182–0.215) 1.47 x 10–9 10.1 x 10–9 
a Numbers in parentheses are 95% CI. Mean of data from n = 6–8 experiments. 
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4.3.2 Influence of C-terminal carboxylation and N-terminal truncation of LsIA 
Conotoxins typically have a high degree of post-translational modification [8, 9], with 
C-terminal amidation shown to influence structure and enhance target specificity [9]. 
Native α-conotoxin LsIA also undergoes C-terminal amidation. Our collaborators 
synthesised a C-terminally carboxylated analogue of LsIA (LsIA#) to examine its 
activity at different nAChR subtypes. Interestingly, LsIA# was ~ three-times less 
potent at the α7 subtype and ~ three-fold more potent at the α3β2 subtype [Figure 
4.4].  
α7 nAChR
-9 -8 -7 -6
0.0
0.2
0.4
0.6
0.8
1.0
1.2 LsIA#
LsIA
[∆1]LsIA
[∆1-2]LsIA
[Peptide] (M)
Re
la
tiv
e 
C
ur
re
nt
 A
m
pl
itu
de
α3β2 nAChR
-10 -9 -8 -7 -6 -5
0.0
0.2
0.4
0.6
0.8
1.0
1.2
LsIA
LsIA#
[∆1]LsIA
[∆1-2]LsIA
[Peptide] (M)
Re
la
tiv
e 
C
ur
re
nt
 A
m
pl
itu
de
A B
 
Figure 4.4: Influence of N-terminus truncation and C-terminus carboxylation of 
LsIA on ACh-evoked current inhibition at the α7 (A) and α3β2 (B) nAChR 
subtypes. Concentration–response curves for LsIA#, [∆1]LsIA and [∆1–2]LsIA 
inhibition gave IC50 values of 30.7 nM (95% CI, 21.7–43.4 nM; nH  = –1.5 ± 0.4), 23 
nM (95% CI, 19.3–27.5 nM; nH  = –2.0 ± 0.3) and 44.1 nM (95% CI, 37.1–52.4 nM; 
nH  = –2.5  ± 0.4) at α7, respectively; and 3.3 nM (95% CI, 2.2–5.1 nM; nH  = –1.0 ± 
0.2), 56.2 nM (95% CI, 40.4–78.2 nM; nH  = –1.0 ± 0.2) and 92.4 nM (95% CI, 69.3–
123.3 nM; nH  = –0.9 ± 0.1) at α3β2, respectively. The broken line represents the 
carboxylated LsIA (LsIA#) concentration–response curve. Data represents means ± 
SEM, n = 4–7. 
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α-Conotoxin LsIA contains a unique N-terminal serine residue. Truncation of the four 
residue N-terminal tail of α-GID has been shown to influence activity at neuronal 
nAChRs [10]. Our collaborators synthesised two truncated analogues, [∆1]LsIA 
(lacking the serine at position 1) and [∆1-2]LsIA (lacking the serine at position 1 and 
glycine at position 2). [∆1]LsIA- and [∆1-2]LsIA-amidated peptides were two-fold 
and four-fold less potent at the α7 subtype than LsIA, respectively [Figure 4.4 and 
Table 4.2]. They were also five-fold and nine-fold less potent at the α3β2 subtype 
than LsIA, respectively [Figure 4.4 and Table 4.2]. These results indicate that the N-
terminal sequence plays a major role in LsIA potency. 
 
 
Table 4.2: Half-maximal inhibitory concentrations (IC50) and Hill slope (nH) 
values from concentration–response curves for LsIA and its analogues at the 
α3β2 and α7 nAChR subtypesa.  
 α3β2  α7 
Peptide IC50 (nM) nH   IC50 (nM) nH 
LsIA 10.3 (8.8–12.1) –1.3 ± 0.1 
 
10.1 (8.7–11.6) –2.1 ± 0.4 
[∆1] LsIA 56.2 (40.4–78.2) –1.0 ± 0.2 
 
23 (19.3–27.5) –2.0 ± 0.4 
[∆1–2] LsIA 92.4 (69.3–123.3) –0.9 ± 0.1 
 
44.1 (37.1–52.4) –2.5 ± 0.3 
LsIA# 3.3 (2.2–5.1) –1.0 ± 0.2   30.7 (21.7–43.4) –1.5 ± 0.4 
a Numbers in parentheses are 95% CI. Mean of data from n = 5–8 experiments.
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4.4 DISCUSSION 
α-Conotoxins evolved as selective probes that target nicotinic receptors, parallel with the 
phylogenetic evolution of marine cone snails belonging to the genus Conus. This corresponds 
with the structural similarities between various conotoxins, including conserved cysteine 
framework and residues. The cysteine framework of α-conotoxins (CC-C-C) divides the 
peptide sequence into two loops, from which they are classified into various subclasses. A 
high-sequence homology or conserved residues are observed across various α-conotoxins 
[Table 4.3].  
 
Table 4.3: Sequence alignment of LsIA and α-conotoxins. 
α-Conotoxin Sequence nAChR selectivity Reference 
Ls1a   SGCCSNPACRVNNPNIC* α3β2≈α7>α3α5β2 This study 
GID IRDγCCSNPACRVNNOHVC# α7≈α3β2>α4β2 [10] 
ArIA IRDECCSNPACRVNNOHVCRRR# α7>α3β2 [11] 
ArIB   DECCSNPACRVNNPHVCRRR# α7≈α6β2*>α3β2 [11] 
MII    GCCSNPVCHLEHSNLC* α3β2≈α6β2*>α6β4 [12] 
RegIIA     GCCSHPACNVNNPHIC* α3β2>α3β4> α7 [13] 
OmIA    GCCSHPACNVNNPHICG* α3β2>α7>α6β2* [14] 
GIC     GCCSHPACAGNNQHIC* α3β2≈α6β2*>α7 [15] 
Mr1.1    GCCSHPACSVNNPDIC* α3β2>α3β4>α7 [16] 
PnIA    GCCSLPPCAANNPDYC* α3β2>α7 [17] 
AuIB    GCCSYPPCFATNPD-C* α3β4 [18] 
BuIA    GCCSTPPCAVLY---C* β2*>β4* [19] 
RgIA    GCCSDPRCRYR----CR# α9α10>>α7 [20] 
* denotes an amidated C-terminus; #, free carboxyl C-terminus; γ, γ-carboxyglutamate. Cysteine 
residues are highlighted yellow. Residues homologous to LsIA are highlighted grey. 
 
Previous studies that aimed to understand the molecular interactions involved in α-conotoxin 
subtype-selective antagonism of nAChRs used X-ray studies of co-crystal AChBP and ImI 
structures, [A10L,D14K]PnIA and [A10L]TxIA. They revealed significant interaction 
between loop 1 (residues between Cys II and III) and the principal face of the receptor [21, 
22]. The loop 2 residues of the peptide were shown to majorly interact with the 
complementary side of the receptor. These studies identified the general role of loop1 in 
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peptide affinity, while loop2 contributes to the subtype selectivity of the α-conotoxin. Also, 
structurally, loop1 plays a vital role in the secondary structure of the peptide (presence of α-
helix). NMR studies revealed significant disruption of the peptide’s classic ω-globular 
structure upon mutagenesis [23]. This was also indicated through the presence of conserved 
residues within loop1 of various subclasses of α-conotoxins [Table 4.3]. AChBP co-crystal 
studies also showed significant hydrogen bonding and van der Waals interactions between the 
Ser-, Pro- and Gly-conserved residues of loop1 in almost all α-conotoxins and the receptor 
binding pocket [21]. 
 
α-Conotoxin LsIA is a new peptide isolated from C. limpusi that potently inhibits nAChRs. It 
is an α4/7 conotoxin and exhibits equipotent inhibition at α3β2 and α7 subtypes. Pairwise 
sequence alignment shows strong homology between LsIA and previously characterised α-
conotoxins that target the α3β2 and α7 nAChR subtypes.  
 
LsIA exhibits two sequence motifs, namely –SXPA– and –NNP–. These motifs are also found 
among OmIA, RegIIA, Mr1.1 and ArIB conotoxins, which have a similar pharmacological 
profile to LsIA [Table 4.3]. The structural and functional significance of the –SXPA– motif 
within loop1 of conotoxins was discussed earlier.  
 
Mutation of Ser and Pro residues to Ala in α-conotoxin GID led to significant activity loss at 
α7 and α7/α3β2 nAChR subtypes, respectively [24]. A similar interaction between LsIA and 
α7 and α3β2 nAChR subtypes is expected.  
 
Along with conserved motifs, LsIA exhibits a unique N-terminal Ser residue. In this study, I 
examined the functional implication of the N-terminal sequence, including the most common 
post-transcriptional modification found in the α-conotoxins: C-terminal amidation. The 
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influence of the N-terminal sequence was previously examined in α-conotoxin GID. Initial 
studies with [∆1-4]GID showed significant activity loss at the α4β2 nAChR subtype, but no 
change in IC50 was observed at α7 and α3β2 nAChR subtypes [10]. Interestingly, a noticeable 
loss in activity at α7 and α3β2 subtypes was observed when the first three residues were 
deleted ([∆1-3]GID). However, [∆1] and [∆1-2]GID truncation only affected α3β2 inhibition 
[24].  
 
A similar trend was observed in LsIA, where truncation of first and second residues lead to 
considerable loss in activity at the α7 and α3β2 nAChR subtypes [Figure 4.4 and Table 4.2]. 
This activity loss was more prominent at the α3β2 subtype, with ~5-fold reduction, than at the 
α7 subtype, which only showed ~2-fold less activity, with [∆1]LsIA. This effect was further 
amplified for [∆1-2]LsIA, which triggered ~9-fold and ~4-fold activity loss at α3β2 and α7 
nAChR subtypes, respectively. Surprisingly, the most striking effect on peptide function was 
observed when the C-terminus was carboxylated (LsIA#). This modification led to a ~3-fold 
increase in potency at the α3β2 nAChR subtype, but caused an opposite effect at the α7 
nAChR subtype, with a ~3-fold activity loss.  
 
In α-conotoxin GID, C-terminus carboxylation only influenced peptide activity at the α3β2 
nAChR subtype [24]. One explanation for this is the formation of intra-molecular salt bridges 
or hydrogen bonds when the free C-terminus carboxyl group is incorporated into LsIA.  
 
In this study, I report a difference in pharmacological activity of LsIA at α5-containing 
nAChRs, with LsIA being 3-fold less potent at the α3α5β2 subtype than at the α3β2 subtype. 
Unlike the α3 subunit, the α5 subunit is an auxiliary subunit that does not form functional 
receptors when expressed with β2 or β4 [25]. However, its role as the fifth subunit in nAChR 
pharmacology and physiology has recently gained prominence, because it influences 
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conductance [26], agonist sensitivity [27] and ion permeability [7]. Previous studies of α-
conotoxin Vc1.1 at α5-containing nAChRs showed no significant IC50 change [28]. 
Interestingly, kinetic analysis of LsIA inhibition revealed faster onset of block (kon) at the 
α3α5β2 subtype than at the α3β2 subtype, which contributes to the 3-fold lower ki value at 
α3α5β2. No significant difference in koff was observed between the α3α5β2 and α3β2 nAChR 
subtypes. LsIA off-rate kinetics was slower at the α7 subtype than at the α3β2 and α3α5β2 
subtypes. Also, a significant ~ 7-fold difference was observed in the ki and IC50 values at the 
α7 subtype. This difference could be due to a higher Hill slope (nH) of –2.1 at the α7 subtype 
than at the other subtypes, indicating positive peptide binding cooperativity.  
 
4.5 SUMMARY AND CONCLUSION 
LsIA is the first peptide isolated from the venom of C. limpusi. Structure–activity data 
collected in this study indicates N-terminal and C-terminal sequences have unique and 
specific roles in the pharmacology of this peptide. The N-terminal sequence (Ser1 and Gly2 
residues) contributes to nAChR binding affinity, while C-terminus modification imparts 
subtype selectivity. While a number of α-conotoxins that potently inhibit α3β2 and α7 
nAChR subtypes exist [Table 4.3], I report differences between α-conotoxin LsIA’s 
pharmacology and kinetics of inhibition in the presence and absence of the auxiliary α5 
subunit. In conclusion, this study provides vital information to improve our understanding of 
nAChR inhibition and aid development of novel analogues with improved subtype selectivity. 
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CHAPTER 5 
 
Novel αD-conotoxin GeXXA from Conus generalis  
reveals unique nAChR binding mechanism 
 
Conus generalis 
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5.1 INTRODUCTION 
As mentioned earlier (Chapter 1, Section 2), various bioactive peptides have been identified 
from the venom of cone snails belonging to the genus Conus, labelled conotoxins. The 
disulphide-rich peptides targeting nAChRs are grouped into various superfamilies, based on 
their structural and functional properties: the A- (α- and αA-conotoxins), M- (ψ-conotoxins), 
S- (αS-conotoxins) and C-conotoxins (αC-conotoxins) [1].  
 
Conotoxins from the D-superfamily were only recently discovered and functionally 
characterised [2, 3]. First isolated from the venom C. vexillum, three novel αD-conotoxins, 
αD-VxXIIA, αD-VxXIIB and αD-VxXIIC, were functionally characterised as potent 
inhibitors of α7- and β2-containing neuronal nAChRs [2]. Kauferstein et al. (2009) identified 
and analysed two new αD-conopeptides from the vermivorous snails Conus mustilinus (αD–
M) and Conus capitaneus (αD–Cp). These peptides have a pharmacological profile similar to 
that of αD-VxXIIA with a 72% sequence homology [Table 5.1] [4].  
 
In the present study, we identified novel αD-conotoxin GeXXA from the venom of Conus 
generalis. Functional characterisation revealed αD-GeXXA non-selectively inhibits nAChRs, 
an action not previously identified in αD-conotoxins, which usually exhibit characteristic 
subtype selectivity. We also report the first synthesis of a functionally active monomeric αD-
GeXXA isoform. 
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Table 5.1: Sequence alignment of αD-conotoxin GeXXA with other, previously discovered αD-conotoxins. 
αD-Conotoxin    Sequence  nAChR selectivity  Reference 
GeXXA DVH-RPCQSVRPGRVWGKCCLTRLCSTMCCARADCTCVYHTWRGHGCSCV- α7>α3*>αβδγ  This study 
Ms20.3 DVR--ECQVNTPGSSWGKCCMTRMCGTMCCARSGCTCVYHWRRGHGCSCPG α7>β2* [4, 5] 
Cp20.3 EVQ--ECQVDTPGSSWGKCCMTRMCGTMCCSRSVCTCVYHWRRGHGCSCPG α7>β2* [4, 5] 
VxXXA D--VQDCQVSTPGSKWGRCCLNRVCGPMCCPASHCYCVYHRGRGHGCSC-- α7>α3β2 [2] 
VxXXB DDE-SECIINTRDSPWGRCCRTRMCGSMCCPRNGCTCVYHWRRGHGCSCPG α7>β2*>αβδγ [2] 
VxXXC DLR--QCTRNAPGSTWGRCCLNPMCGNFCCPRSGCTCAYNWRRGIYCSC-- α7>β2* [2] 
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5.2 AIMS 
 
5.2.1 Characterisation of αD-conotoxin GeXXA isolated from Conus generalis 
 To determine the pharmacological potency and selectivity of dimeric and 
monomeric GeXXA at recombinant nAChR subtypes expressed in 
Xenopus oocytes using the two-electrode voltage clamp technique.  
 
5.2.2 Receptor hybrid studies 
 To identify the site where dimeric and monomeric αD-conotoxin GeXXAs 
bind with nAChRs, and the molecular mechanism behind their inhibition 
of nAChRs. 
 
5.2.3 Significance 
 This study, in conjunction with modelling simulations our collaborators 
are doing, could shed light on the molecular mechanism behind the αD-
conotoxins interaction with nAChR subtypes.  
 αD-conotoxins represent a novel class of nAChR-inhibiting peptides as 
potential neurophysiological tools and drug therapeutics. This study could 
also provide valuable information that could aid novel peptide design and 
the development of future drugs. 
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5.3 RESULTS 
5.3.1 Concentration-dependent inhibition of α3-containing nAChRs by αD-conotoxin 
GeXXA 
To examine the pharmacological activity of αD-conotoxin GeXXA at nAChRs, it was tested on 
ACh-evoked currents mediated by different nAChR subtypes expressed in Xenopus oocytes. 
GeXXA (1 µM) had no or little effect on α4β2 and α4β4 subtypes, but inhibited α3β4 and 
muscle (α1β1εγ) by 70–80%, and inhibited α9α10, α7 and α3β2 subtypes completely [Figure 
5.1(A)].  
 
Concentration–response curves showed GeXXA was more selective for α3-containing than 
α4-containing nAChR subtypes [Figure 5.1(B)]. It was most potent at the α7 nAChR subtype, 
with an IC50 of 210 nM (95% CI, 174–253) and Hill slope (nH) of –1.6 ± 0.2. The IC50 (95% 
CI) and Hill slope values from concentration–response curves for the inhibition of various 
nAChR subtypes are summarised in Table 5.2.  
 
Table 5.2: Pharmacological profile of dimeric αD-conotoxin GeXXA inhibition of 
various nAChRs. 
 nAChR subtype IC50 (95% CI) nH 
α7 210 nM (174–253) –1.6 ± 0.2 
α3β2 498 nM (407–609) >> –1.0 
α3β4 614 nM (491–768) –2.1 ± 0.4 
α4β2 > 3 µM – 
α4β4 > 3 µM –0.9 ± 0.2 
αβδγ 743 nM (606–911) –1.6 ± 0.2 
All data points indicate mean ± SEM; n = 4–7. 
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Figure 5.1: Dimeric αD-conotoxin GeXXA inhibition of various nAChR subtypes. (A) 
Superimposed current traces obtained in the absence (control) and presence of 300 nM of 
dimeric αD-conotoxin GeXXA inhibition at the (i) α7 nAChR subtype and (ii) α3β2 nAChR 
subtype. (B) Concentration–response curves obtained for dimeric αD-conotoxin GeXXA 
inhibition of nAChR subtypes. Dimeric GeXXA (3 µM) non-selectively inhibited all nAChR 
subtypes, except α4β2. The highest potency of inhibition was observed at the α7 nAChR 
subtype. The IC50 (95% CI) and Hill slope (nH) values from concentration–response curves 
are summarised in Table 5.2. All data points represent the mean ± SEM; n = 4–7. 
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5.3.2 Monomeric αD-conotoxin GeXXA selectively inhibits the α9α10 nAChR subtype 
We describe for the first time monomeric αD-conotoxin GeXXA inhibition of nAChRs. When 
tested on various nAChR subtypes, 1 µM of monomeric GeXXA completely inhibited the 
α9α10 nAChR subtype, but had little or no activity at other nAChR subtypes. This 
antagonism of α9α10 was also reversible [Figure 5.2(A)], unlike dimeric αD-conotoxin 
GeXXA which irreversibly inhibited α9α10 subtype [data not shown]. The concentration–
response curve obtained for the monomeric GeXXA at α9α10 nAChR gave an IC50 of 198 
nM (95% CI, 164–238; nH = –1.7 ± 0.3) [Figure 5.2(B)]. 
 
 
Figure 5.2: α9α10 hybrid nAChR inhibition by monomeric αD-conotoxin GeXXA. (A) 
Superimposed ACh-evoked currents obtained in the absence (control) and presence of 1 µM 
of monomeric αD-contoxin GeXXA at human and rat α9α10 nAChR subtype. (B) Monomeric 
αD-conotoxin GeXXA was 10-fold less potent at the human α9α10 nAChR subtype than at 
the rat α9α10 nAChR subtype, whereas no change was observed at the hybrid hα9rα10 
receptor. All data points indicate mean ± SEM; n = 4–7. 
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5.3.3 α9α10 hybrid nAChR studies reveal the site of monomeric αD-conotoxin GeXXA 
binding 
The difference between dimeric and monomeric αD-conotoxin GeXXA inhibition of the 
α9α10 nAChR subtype was further investigated on hybrid receptors using human and rat α9 
and α10 nAChR subunits. When initially tested on human α9α10, monomeric α-D GeXXA 
was 10-fold less potent compared with rat α9α10. However, similar potency was observed on 
the hybrid hα9rα10 receptor to that of rat α9α10 subtype [Figure 5.2(B)].  
 
Concentration–response curves for monomeric αD-conotoxin GeXXA inhibition of rat, hybrid 
and human α9α10 nAChR subtypes gave IC50 values of 198 nM (95% CI, 164–238; nH = –1.7 
± 0.3), 224 nM (95% CI, 194–258; nH = –1.4 ± 0.1) and 2.02 µM (95% CI, 1.82–2.25; nH = –
1.7 ± 0.1), respectively. All data points represent the mean ± SEM; n = 4–7. 
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5.4 DISCUSSION AND CONCLUSION 
Conotoxins are invaluable pharmacological tools, each with unique structural and functional 
features. αA-Conotoxins consist of up to 30 amino acid residues and generally characterised 
by their competitive antagonism of muscle nAChRs, while ψ-Conotoxins are known to be 
non-competitive muscle nAChR antagonists [6]. 
 
While there have been significant advances in developing our understanding of nAChRs, 
much of their physiological role and pharmacology of these unique peptides on nAChRs is 
still unknown.  
 
D-superfamily conotoxins consist of 45–50 amino acid residues and have characteristic 10 
cysteine residue framework [Table 5.1] [5]. They have various structural and functional 
features. First, several post-translational modifications, such as carboxylation and 
hydroxylation, are seen in native peptides. Second, native peptides occur as homodimers 
connected by disulphide bonds [4]. αD-conotoxin GeXXA is a disulphide-linked homodimer 
of two identical peptides and consists of 50 amino acid residues with 10 cysteines [Figure 
5.3].  
 
Figure 5.3: The sequence and disulphide linkage of αD-conotoxin GeXXA. For clarity, 
only the N-terminal sequence of the second subunit is shown.  
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Previous pharmacologically characterised αD-conotoxins were shown to be non-competitive 
muscle and neuronal nAChR antagonists, with selectivity for α7- and β2-containing receptors 
[2]. However, even though each GeXXA peptide chain shared high homology with other 
known αD-conotoxins [Table 5.1], αD-GeXXA exhibited concentration-dependent inhibition 
of various nAChR subtypes, with selectivity for α7 and α3-containing nAChRs. αD-GeXXA 
inhibits α7 (IC50 210 nM), α3β2 (IC50 498 nM), α3β4 (IC50 614 nM) and muscle (α1β1δγ) 
(IC50 743 nM) nAChR subtypes, and weakly inhibits α4β2 and α4β4 nAChR subtypes (IC50 > 
3 µM). However, its inhibition of both rat and human α9α10 nAChR subtypes was 
irreversible, indicating that it binds tightly to these receptors.  
 
The crystal structure of native αD-GeXXA [contributed to this study by collaborators] 
provided further insight into its unique pharmacological activity and mechanisms of action. 
Structures at 1.5 Ǻ resolution revealed an N-terminal domain (NTD, residues 1–20) and a C-
terminal domain (CTD, residues 21–50) in each peptide chain, arranged in an approximately 
2-fold symmetric architecture. An interchain disulphide bond between Cys6 of one chain and 
Cys18 of another chain within the NTD facilitates αD-GeXXA dimerisation [Figure 5.4]. 
 
Figure 5.4: The crystal structure of αD-conotoxin GeXXA. The NTDs of two GeXXA 
subunits are shown in green and light green. The CTDs are represented in orange and light 
orange. The disulphide bonds are colored yellow. [Provided to this study by collaborators]. 
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We report the first synthesis of αD-GeXXA’s C-terminal domain (CTD) and its activity. The 
isolated CTD adopts a canonical inhibitory cysteine knot (ICK) disulphide linkage. When 
tested on various nAChR subtypes, αD-GeXXA-CTD selectively and reversibly antagonises 
the rat α9α10 nAChR subtype, with an IC50 of 198 nM, but is 10-fold less potent at the human 
α9α10 nAChR subtype (IC50 2.02 µM). Hybrid receptor studies indicate that the α10 nAChR 
subunit contributes to the difference between αD-GeXXA’s potency for human and rat α9α10 
nAChR subtype.  
 
These results indicate that the α10 nAChR subunit is a major binding site for αD-conotoxin 
GeXXA. Peptide sequence alignment revealed residue differences between the extracellular 
domains of mature human and rat α10 subunits [Figure 5.5]. Molecular dynamics simulations 
[contributed to this study by collaborators] indicate a two-site binding interaction between 
αD-GeXXA and the His7 of the α10 subunit. Recently, similar hybrid-receptor studies of the 
α9α10 nAChR subtype found that α-conotoxin Vc1.1 and RgIA preferentially bound to the 
α10α9 pocket [3, 7]. These findings are also supported by electrophysiological data that show 
Hill slope values > 1 for αD-GeXXA interaction with various nAChRs, which indicates a 
positive cooperative binding mode. The Hill equation has been extensively used to aid 
understanding of the complex pharmacokinetic and pharmacodynamic models of drug–
receptor interaction [8-10].  
 
This study is the first to report monomeric αD-conotoxin activity, and gives insight into αD-
conotoxin GeXXA’s novel binding mechanism at nAChRs. 
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Figure 5.5: Pairwise sequence alignment of the ACh-binding site of the mature α10 subunit peptide. This alignment reveals the difference 
between human and rat residues (background white). The mature α10 subunit peptide lacks the signal sequence (first 25 residues). Peptide sequences 
were obtained from the NCBI Protein online database. 
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CHAPTER 6 
Dicarba modification of α-conotoxins exhibits differential selectivity  
for nAChRs and GABAB receptors 
 
Conus victoriae 
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6.1 INTRODUCTION 
 
6.1.1 Conotoxins - Conus victoriae and Conus regius 
α-Conotoxins in the venom of the marine cone snails, are short disulphide-bonded peptides 
ranging from 12–30 amino acids. These peptides specifically target nAChR subtypes and have 
potential therapeutic applications. Conus victoriae and Conus regius venoms gained a special 
interest, due to identification of two novel peptides, α-conotoxins Vc1.1 and RgIA, 
respectively. These peptides have exhibited analgesic properties in rat neuropathic pain 
models [1, 2].  
 
α-Conotoxins Vc1.1 and RgIA belong to the cysteine framework I family (CCXnCXmC) and 
exist in a globular conformation with I–III and II–IV disulphide connectivity in native form 
[3]. Both of these peptides were first identified using a cDNA approach [4, 5]. Vc1.1 is 16 
amino acids in length and belongs to the α4/7 subclass of conotoxins. Like most conotoxins, 
Vc1.1 exhibited various post-translational modifications, including C-terminus amidation, 
hydroxylation of Pro6 and γ-carboxylation of Glu14 residues. This modified peptide, called 
vc1a, was identified in the venom of Conus victoriae and is the native form of Vc1.1 [6]. On 
the other hand, RgIA is an α4/3 conotoxin, consisting of 12 amino acids, and lacks post-
translational modification.  
 
6.1.2 The molecular mechanism of analgesia 
The involvement of nAChRs in pain pathways is now well established [7]. However, the role 
of nAChR subtypes in pain pathways and the molecular mechanism of these pathways are yet 
to be elucidated. Various small molecule compounds acting as α4β2 and α7 nAChR 
antagonists are the primary leads for pain therapeutics [8]. However, the identification of α-
conotoxins as nAChR subtype-selective probes has led to the development of novel drugs to 
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treat neuropathic pain [9]. A major breakthrough came with the discovery of α-conotoxins 
Vc1.1 and RgIA, which have acute and cumulative anti-nociceptive effects in chronic 
constriction nerve injury (CCI) and partial sciatic nerve ligation (PSNL) rat models of 
neuropathic pain [1, 2]. Subcutaneous or intramuscular administration of these peptides 
alleviated mechanical hyperalgesia and allodynia. This effect lasted up to 24 h post-
administration without the rats developing a tolerance to the drug. In addition, Vc1.1’s 
analgesic effects lasted up to one week after treatment was ceased [10]. 
 
The pharmacological profiles of Vc1.1 and RgIA were only established three years after their 
analgesic properties were identified. Initial electrophysiological studies using synthetic Vc1.1 
confirmed the α3β4 nAChR subtype is its pharmacological target, with an IC50 of 3 µM [11]. 
However, concurrent studies revealed Vc1.1 and RgIA also potently inhibit the α9α10 nAChR 
subtype, with an IC50 of 64 nM and 5 nM, respectively [4, 12]. These studies suggested the 
α9α10 nAChR subtype as a novel therapeutic target for neuropathic pain.  
 
Recent studies have also uncovered a new biological target for both of these peptides. Vc1.1 
and RgIA inhibit high voltage-activated (HVA) calcium channel currents via GABAB 
receptor activation, which suggests these α-conotoxins may mediate a novel pain pathway 
[13-15].  
 
6.1.3 The α9α10 nAChR subtype: expression and function 
Of the various nAChR subunits, only the α7 and α9 subunits form homopentamers, and the 
α10 subunit assembles only with the α9 subunit to form functional receptors [16]. Co-
assembly with the α10 subunit also significantly increases the expression of α9α10 nAChRs 
[17]. α9 and α10 subunits are expressed in various tissues, such as skin, dorsal root ganglia 
(DRG), pars tuberalis of the pituitary gland, and cochlear hair cells [10]. In the auditory 
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system, which is composed of cochlear hair cells, α9-containing receptors mediate the 
synaptic transmission, and therefore modulate auditory stimuli [18]. In skin, α9 and α10 
subunits regulate the cell-adhesion properties of keratinocytes and modulate wound-healing 
(re-epithelialisation) [19, 20]. While α9 and α10 subunits are implicated in cholinergic 
signalling in the above-mentioned tissues, their precise subunit stoichiometry is yet to be 
determined. Although α9 can form a functional homomeric receptor, the expression of α10 
subunit was found to be necessary for synaptic transmission in cochlear cells [21]. 
Furthermore, Plazas et al. (2005) showed that α9α10 when recombinantly expressed in 
oocytes, stoichiometry of (α9)2(α10)3 was observed [22].  
 
6.1.4 α-Conotoxin drug development: limitations and strategies  
The nature of the compound is an important aspect of drug development, because it 
determines the drug’s side effects. While the peptidic nature of α-conotoxins is a unique 
advantage for drug development, it is also their Achilles’ heel. α-Conotoxins are susceptible 
to natural peptidic degradation, which drastically affects their bioavailability and half-life. 
The functional impediment of α-conotoxins via peptidic-degradation can result from a 
proteolytic attack on the N- and/or the C-terminus of the peptide, or from disruption 
(scrambling) of the disulphide linkage within the α-conotoxin.  
 
Various strategies to improve α-conotoxin stability have been implemented, such as 
cyclisation and selenocysteine modification. Peptide cyclisation has been shown to counter 
the proteolytic degradation problem in Vc1.1, RgIA and other peptides [23, 24]. The α-
conotoxin three-dimensional structure is dominated by a helical structure shaped by a 
conserved disulphide framework. The most predominant I–III and II–IV disulphide 
connectivity is found in native α-conotoxins and folds the peptide into globular conformation. 
However, the disulphide connectivity of α-conotoxins can interchange under oxidative and 
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reduced conditions to form ribbon (I–IV and II–III disulphide bonds) or bead (I–II and III–IV 
disulphide bonds) conformations. 
 
Peptide exploitation in research and clinical settings has also been hampered by the lability of 
the disulphide bridges that are essential for conotoxin structure and activity [25]. Alteration of 
disulphide linkage by methods such as selenocysteine modification broke new ground in drug 
development [26]. Replacing the cysteine bridges with non-reducible dicarba links has also 
been identified as a novel solution to the lability problem. It was shown to significantly 
improve α-conotoxin ImI stability, while its functional activity remained comparable with that 
of the native peptide.  
 
Here, I explore the functional implications of this approach on novel analgesic α-conotoxin 
Vc1.1 and RgIA, which inhibit HVA calcium channel currents via GABAB receptor 
activation and α9α10 and α3β4 nAChR subtypes. 
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6.2  AIMS 
6.2.1 Characterisation of dicarba modified α-conotoxins Vc1.1 and RgIA. 
 To functionally characterise regioselective dicarba analogues of α-
conotoxins Vc1.1 and RgIA using two-electrode voltage-clamp technique 
in Xenopus oocytes expressing recombinant nAChR subtypes. 
 
6.2.2 Significance  
 This study, in conjunction with structural studies by our collaborators, 
could provide a detailed understanding of the functional implications of 
dicarba modification on the Vc1.1 and RgIA activity at nAChRs.  
 It could also provide valuable information about the development of 
dicarba peptides as novel drugs to treat neuropathic pain. 
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6.3 RESULTS 
6.3.2 Regioselective dicarba Vc1.1 analogues exhibit differential activity at α9α10 
nAChR subtypes 
The functional effects of dicarba modification on Vc1.1 was tested on recombinant α9α10 and 
α3β4 nAChR subtypes heterogeneously expressed in Xenopus oocytes using the two-electrode 
voltage-clamp technique. When tested, cis- and trans-[3,16]-dicarba Vc1.1 analogues (3 µM) 
inhibited the α9α10 nAChR subtype by 24% and 54%, respectively, but the [2,8]-dicarba 
Vc1.1 analogue showed no inhibitory effects [Figure 6.1(A)]. A similar trend was observed 
for these peptides at the α3β4 nAChR subtype [Figure 6.1(B)]. 
 
Figure 6.1: Percentage inhibition of ACh-evoked currents by dicarba Vc1.1 analogues (3 
µM) at α9α10 (A) and α3β4 (B) nAChR subtypes. All data represent the mean ± SEM; n ≥ 
3. 
 
A concentration–response analysis gave an IC50 of 2.8 µM (95% CI, 2.0–4.1 µM) and a Hill 
slope of –1.3 ± 0.3 (n = 4) for trans-[3,16]-dicarba Vc1.1. The cis isomer was ~ five-fold less 
active, with an IC50 of 12.5 µM (95% CI, 5.6–27.9 µM) and a Hill slope of –0.8 ± 0.2 (n = 4) 
[Figure 6.2(C)]. 
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Figure 6.2: Dicarba Vc1.1 analogues concentration-dependent inhibition of ACh-evoked 
currents at the α9α10 nAChR subtype. Superimposed ACh (50 µM)-evoked current traces 
mediated by (A) α9α10 and (B) α3β4 nAChR subtypes in the absence (control) and presence 
of 3 µM of [3,16]-trans-dicarba Vc1.1 and [3,16]-cis-dicarba Vc1.1. (C) Concentration–
response curves for Vc1.1 and dicarba Vc1.1 analogue inhibition of the α9α10 nAChR 
subtype. All data represents mean ± SEM; n ≥ 4. 
 
6.3.2 Dicarba modification of RgIA confers similar pharmacological effects to those of 
Vc1.1 
In this study, each of the peptides was compared with native RgIA on α9α10 and α7 nAChRs 
expressed in Xenopus oocytes. Native RgIA reversibly inhibited ACh-evoked currents 
mediated by α9α10 and α7 nAChRs in a concentration-dependent manner, with an IC50 of 5.5 
nM (nH = −1.3) and 3.3 µM (nH = −0.9), respectively [4].  
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At the α9α10 nAChR subtype, cis- and trans-[3,12]-dicarba RgIA analogues (3 µM each) 
inhibited ACh-evoked currents by 35.4 ± 1.5% and 31.5 ± 2.1% (n = 3), respectively [Figure 
6.3(A)(i)]. The cis isomer exhibited an IC50 of 1.15 µM (95% CI, 0.84–1.55 µM) and a Hill 
slope of −1.9 ± 0.4 (n = 3). The trans isomer was 1.3-fold less active, with an IC50 of 1.47 µM 
(95% CI, 1.01–2.15 µM) and a Hill slope of −1.2 ± 0.2 (n = 3) [Figure 6.3(B)].  
 
In contrast, at the α7 nAChR subtype, cis-[3,12]-dicarba RgIA inhibition of ACh-evoked 
currents was similar to that of native RgIA, with an IC50 of 3.73 µM (95% CI, 1.42–9.82 µM) 
and a Hill slope of −1.6 ± 0.6 [Figure 6.3(B)]. The trans-isomer was inactive at α7 when 
tested at a concentration of 3 µM [Figure 6.3(A)(ii)]. Replacing the [2,8]-cystine bridge 
significantly abolished nAChR activity, with both the cis- and trans-[2,8]-dicarba RgIA 
inactive when tested at 10 µM at the α9α10 nAChR subtype [data not shown]. 
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Figure 6.3: [3,12]-Dicarba RgIA analogue inhibition of ACh-evoked currents at rat 
α9α10 and human α7 nAChRs expressed in Xenopus oocytes. (A) (i) Superimposed ACh 
(50 µM)-evoked currents mediated by α9α10 nAChRs in the absence (control) and presence 
of 3 µM each of cis-[3,16]-dicarba RgIA and trans-[3,16]-dicarba RgIA. (ii) Superimposed 
ACh (200 µM)-evoked currents at α7 nAChRs in the absence (control) and presence of 3 µM 
each of cis-[3,16]-dicarba RgIA and trans-[3,16]-dicarba RgIA. (B) Concentration–response 
curves for cis-[3,12]-dicarba RgIA gave an IC50 of 1.15 µM (95% CI, 0.84–1.55 µM) and a 
Hill slope of −1.9 ± 0.4 at the α9α10 nAChR. trans-[3,12]-dicarba RgIA gave an IC50 of 1.47 
µM (95% CI, 1.01–2.15 µM) and a Hill slope of −1.2 ± 0.2 at the α9α10 nAChR. At the α7 
nAChR subtype, cis-[3,12]-dicarba RgIA had an IC50 of 3.73 µM (95% CI, 1.42–9.82 µM) 
and a Hill slope of −1.6 ± 0.6, but trans-[3,12]-Dicarba RgIA was inactive. All data represent 
mean ± SEM; n ≥ 3. 
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6.4 DISCUSSION 
 
6.4.1 Dicarba modification imparts differential pharmacological selectivity to α-
conotoxins Vc1.1 and RgIA 
Dicarba modification of the disulphide bridge imparted differential and significant changes to 
the pharmacological profile of α-conotoxins Vc1.1 and RgIA. Dicarba modification of the 
Cys2–Cys8 disulphide bond in Vc1.1 and RgIA, led to complete loss of activity at nicotinic 
receptors. Both peptides also lost appreciable activity at the α9α10 nAChR subtype when the 
Cys3–Cys16 disulphide bond in Vc1.1 and Cys3–Cys12 disulphide bond in RgIA were 
replaced with dicarba linkage. The [3, 12]-dicarba RgIA analogues are more potent than the 
corresponding dicarba Vc1.1 analogues, and their IC50 change was more prominent than the 
native peptide. NMR structural analysis [experiments carried out by our collaborators; 
data not shown] of these peptides shows a clear perturbation of the three dimensional 
structure of [2,8]-trans-dicarba Vc1.1 and RgIA analogues, which contributes to its loss of 
activity at nAChR subtypes.  
 
While previous point mutation studies of Vc1.1 and RgIA revealed the key residues 
interacting with the α9α10 nAChR subtype, this study and molecular dynamics simulations 
[experiments conducted by our collaborators; data not shown] propose significant 
interaction between the peptides’ disulphide bonds and ACh-binding pocket. Our 
collaborators’ molecular docking studies revealed disulphide stacking interaction between the 
Cys2–Cys8 bond and disulphide of the C-loop of the principal subunit. This interaction was 
shown to be important for α4/7 conotoxin PnIA[A4L,D14K] bound to the AChBP [27]. This 
model is corroborated by the complete loss of activity of the [2,8]-dicarba-modified Vc1.1 
and RgIA peptides. It also explains the significant variance in peptide function, whereas NMR 
studies [conducted by our collaborators] show no significant perturbation except for trans-
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[2,8]-dicarba Vc1.1. Furthermore, when tested, these peptide analogues exhibited opposite 
effects on their corresponding biological targets.  [2,8]-Dicarba Vc1.1 analogues inhibited 
HVA calcium channel currents via GABAB receptor activation in rat DRG neurons, but 
[3,16]-dicarba Vc1.1 peptides were inactive [results published] [28]. Similar results were 
also observed with RgIA dicarba analogues [experiments conducted by our collaborators; 
data not shown]. These results suggest that the CysII–CysIV disulphide bond may interact 
with GABAB receptors in a similar way to that in which the CysI–CysIII bond interact with 
nAChRs. 
 
6.4.2 Molecular determinants of Vc1.1 and RgIA pharmacological selectivity 
Unlike other nAChR subtypes, α9α10 has very unique pharmacological properties, which are 
yet to be fully understood. Various compounds, such as nicotine, cytisine and epibatine, 
which are agonists of α7 and other heteromeric receptors, antagonise the α9α10 nAChR 
subtype [10]. Furthermore, inhibition of α9α10 nAChR by non-cholinergic antagonists, such 
as strychnine (glycine receptor antagonist), represents a distinctive and mixed 
pharmacological property for this receptor subtype [17].  
 
Vc1.1 emerged as novel drug to treat neuropathic pain after various studies showed it’s 
cumulative and long-lasting alleviation of hyperalgesia and allodynia. However, drug 
development of Vc1.1 was stopped at phase 2A of the human clinical trials, because potencies 
at rat and human α9α10 nAChR subtype inhibition differed significantly [29]. Various studies 
that aimed to explain the molecular determinants of Vc1.1 and RgIA identification of their 
pharmacological target, the α9α10 nAChR subtype, were later conducted [3]. Point mutational 
analyses of RgIA revealed that region 5–7 interacts with the α9α10 binding pocket [30]. 
Similar studies using Vc1.1 showed that as well as region 5–7, a second region, 11–15, is 
needed for Vc1.1 activity at the α9α10 subtype [31]. This study also showed significantly 
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increased potency at rat and human α9α10 subtypes when Asn9 was changed to hydrophobic 
residues in Vc1.1 [31].  
 
These studies had two significant effects on the development of Vc1.1 and RgIA as drug 
leads. Firstly, they elucidated the molecular mechanism of inhibition at α9α10, providing vital 
information about the structure–function relationship between these two α-conotoxin classes. 
Secondly, peptide analogues developed in these studies with increased activity at α9α10 
subtype provided new lead compounds to aid in drug development.  
 
6.5 SUMMARY AND CONCLUSION 
α-Conotoxins are subtype-selective nAChR antagonists and established leads for drugs to 
treat various pain conditions [23]. Here, I have outlined various studies that contributed to our 
understanding of the molecular pharmacology of Vc1.1 and RgIA at α9α10 and GABAB 
receptors. These studies have significantly progressed development of these novel α-
conotoxins as pain therapeutics. I have also successfully identified the potential use of dicarba 
modification of these peptides to improve their bioavailability and half-life, and maintain their 
biological activity. My results provide vital information about the molecular mechanism of 
peptide inhibition of the α9α10 nAChR subtype. Together with previous mutational studies, 
synthesis and functionally characterisation of new dicarba analogues that aim to improve 
peptide potency are being carried out.  
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CHAPTER 7 
 
Conclusion & future directions 
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Nicotinic research has significantly grown over the past 30 years. [1-3]. However, there are 
still numerous challenges and questions to be answered that are related to these ligand-gated 
channels [4]. There has also been a prominent shift in the direction of research into nAChRs. 
While previous studies focused on nAChR structure and function, present research aims to 
understand the physiological roles played by various nAChR subtypes [5, 6]. Today, nAChR 
subtypes are implicated in numerous neuronal and non-neuronal diseases, which further 
indicate their vital physiological role [1, 7].  
 
α-Conotoxins, a diverse group of peptides that act as subtype-specific nAChR antagonists, are 
the ideal tool to identify the role played by nAChRs in various physio- and pathophysiological 
processes. Developments in molecular techniques and peptide chemistry have exponentially 
increased the number of α-conotoxins being discovered [8]. However, out of the 700 cone 
snail species, each with 100s of α-conotoxins, only 0.1% have been functionally characterised 
to date [9, 10]. There are also various challenges in the clinical exploitation of these peptides. 
In this thesis, the collaborative studies identify and tackle some of the pressing issues related 
to the therapeutic development of conotoxins, such as nAChR subtype-specific ligand potency 
and selectivity, and α-conotoxin stability under physiological conditions. 
 
α-Conotoxin AuIB is the only peptide known to selectively target the α3β4 nAChR subtype 
with an IC50 of 2.5 µM [11]. In this thesis, I successfully characterised a novel α4/7 conotoxin 
RegIIA, isolated from the venom of Conus regius. This peptide, although active at α3β2 and 
α7 nAChRs, potently inhibited the α3β4 nAChR subtype, making it a significant discovery.  
RegIIA is only the fifth α-conotoxin known to target the α3β4 nAChR subtype. Other 
characterised α-conotoxins known to inhibit the α3β4 nAChR subtype are BuIA, AuIB, PIA 
and PeIA [12]. Unlike α-conotoxin AuIB, which belongs to a unique α4/6 subclass and 
exhibits distinct sequence, RegIIA and other α-conotoxins exhibit high-sequence homology. 
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This made RegIIA an ideal candidate to help us identify and understand the molecular 
determinants governing its α3β4 nAChR subtype antagonism. Using alanine scanning 
mutagenesis, I not only identified the critical residues that interact with each of the nAChR 
subtypes, but also successfully synthesised an analogue that potently and selectively targets 
the α3β4 nAChR subtype. This will be invaluable in deciphering the physiological role played 
by the α3β4 nAChR subtype, and for the design and development of α3β4-selective drugs to 
treat lung cancer and nicotine addiction. 
 
In this thesis, I characterised another α-conotoxin, LsIA, isolated from Conus limpusi. This 
peptide was of special interest, since it contained a unique N-terminal serine amino acid in 
addition to a glycine, which is found in almost all conotoxins. To date, very few α-conotoxins 
have been found to exhibit this N-terminal sequence [12]. Therefore, I examined the 
significance of this sequence, including C-terminus carboxylation, on LsIA’s functional 
activity. While the truncated analogues caused LsIA’s loss in activity at both of its 
pharmacological targets, which was similar to previous studies with α-conotoxin GID [13], C-
terminal carboxylation changed selectivity between the α3β2 and α7 nAChR subtypes. I also 
extended this study to identify the role the α5 nAChR subunit plays in α-conotoxin 
pharmacology. Interestingly, while α5 subunit incorporation into the α3β2 nAChR subtype 
decreased LsIA’s IC50 three-fold, a faster onset of block (kon) was observed at the α3α5β2 
nAChR subtype. Together, these results present a novel strategy for the development of novel 
analogues with improved subtype selectivity and suggest a pharmacological role played by 
the auxiliary α5 subunit in the inhibition of nAChRs by α-conotoxins. 
 
I also functionally characterised a novel conotoxin, GeXXA, which belongs to the D-
superfamily. αD-conotoxins are unique homo-dimeric peptides that non-competitively target 
nAChRs. However, very few peptides from this family have been characterised.  αD-GeXXA 
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selectively inhibits α7 and α3-containing nAChRs and irreversibly inhibits α9α10 nAChR 
subtype. This is the first report of monomeric αD-conotoxin activity, selectively inhibiting the 
α9α10 nAChR subtype. These results present a novel binding mechanism for an αD-
conotoxin and provide future insights for the development of new nAChR antagonists.  
 
Finally, in a collaborative study, I examined the functional implications of dicarba 
modification of the disulphide bonds in α-conotoxins Vc1.1 and RgIA. Both of these peptides 
exhibit analgesic properties and inhibit α9α10 nAChR and N-type calcium channel currents 
via GABAB receptor activation [14]. However, the lability of the disulphide bond has 
hampered clinical exploitation of these and other α-conotoxins.  
 
Dicarba modification of the disulphide bonds has been shown to improve peptide stability 
[15, 16]. I identified a significant reduction in activity for Vc1.1 and RgIA at the α9α10 
nAChR subtype. However, interestingly, regioselective I–III and II–IV dicarba analogues 
exhibited differential selectively towards their biological targets. These results suggest that 
the CysI–CysIII disulphide bond of Vc1.1 and RgIA interacts with α9α10 nAChR subtype 
receptors. This may help us establish a novel strategy for developing subtype-selective 
nAChR antagonists and new leads for stable drugs to treat various pain conditions. 
 
Overall, the studies outlined in this thesis have provided crucial information to improve our 
understanding of the molecular pharmacology and potential therapeutic use of α-conotoxins. 
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